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ABSTRACT
The Role of Arginase I in Ischemic Stroke and Cardiovascular Disease
Ashley Brooke Petrone
Acute ischemic stroke (AIS) is currently the fifth leading cause of death and a leading
cause of long-term disability in the United States. Further, the incidence of AIS is expected
to increase dramatically through year 2030. Despite the current and anticipated burden
of AIS, treatment options for AIS, both acute and chronic, are extremely limited. Tissue
plasminogen activator (tPA) is currently the only FDA-approved drug used to treat AIS;
however, only a small fraction of AIS patients are eligible to receive tPA, and of these,
only roughly 15 percent benefit from treatment with tPA. Given this, there is a crucial need
to develop novel therapeutic options for AIS that may act independently or improve the
efficacy of tPA. The use of human biomarker studies has led to the discovery of several
biomarkers that can be used to diagnose AIS from other pathological conditions and can
also be used to identify therapeutic targets for future therapeutics. Our laboratory has
previously identified arginase 1 (ARG1) as the most significantly upregulated gene in the
blood of AIS patients compared to control; however, the source and functional
significance of this elevation is unclear. ARG1 has been shown to have a broad range of
functions, including mediating the immune system response and vascular function, and
because changes in both immune and vascular function play a role in AIS severity and
recovery, ARG1 may represent a novel prognostic marker and therapeutic target in AIS.
The purpose of this dissertation was to better characterize the role of ARG1 in
AIS and cardiovascular disease (CVD) as a whole. Specifically, to determine how
changes in ARG1 expression may mediate immune function and vascular function, and
how these alterations impact disease incidence, progression, and recovery. Herein, we
have shown that increased ARG1 expression is associated with changes in immune
function that may contribute to post-stroke immunosuppression and poor recovery
following AIS. Further, in addition to mediating the immune response to AIS, increased
ARG1 is also associated with increased arterial stiffness and vascular dysfunction
following AIS. Lastly, we have shown that increased ARG1 expression is associated
with vascular dysfunction outside of AIS, in the context of patients with CVD risk factors.
Our results suggest a potential role for ARG1, as both a diagnostic and prognostic
marker in AIS. We also have evocative evidence to suggest that ARG1 inhibition may
be a potential therapeutic strategy to reduce the incidence and severity of AIS.
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I. Cardiovascular Disease

Total cardiovascular disease (CVD) is the leading cause of death, in the United States
and worldwide, and roughly 1 out of 3 Americans has a degree of CVD[1]. Total CVD is
defined as having at least one of the following conditions: coronary heart disease, stroke,
high blood pressure, and disease of the arteries (Figure 1)[1]. While the slight majority of
CVD cases occur in the population aged >60 years, an almost equal incidence of CVD
occurs in the younger population[1]. This incidence among younger Americans
contributes to the anticipated increased prevalence of CVD over the next decade.
Concordant with the overall CVD prevalence and mortality rate, these increases are
expected to be more dramatic in distinct populations, including rural populations and
geographic areas with low socioeconomic status[1]. Aside from the high mortality rate and
social burden of CVD, the financial burden associated with treating CVD is currently
nearly 320 billion dollars per year and is expected to increase to 918 billion dollars
annually by year 2030[1].

II. Stroke
Stroke represents 16 percent of total CVD cases, and approximately 6.6 million people
worldwide have had a stroke, with roughly 800,000 new strokes occurring annually in the
US[1]. The prevalence of stroke has been reported to range from 6-28%[1], and this wide
range is likely due to both unreported cases and unclear diagnosis of stroke. Similar to
CVD, the prevalence of stroke is expected to increase by 20.5 percent by year 2030[1].
When considered independent of CVD, stroke is currently the fifth leading cause of death
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in the US and second leading cause of death worldwide, and while the mortality rate of
stroke has decreased over the past decade, the number of people living with stroke is
expected to increase, making stroke a leading cause of long-term disability in the US[1].
Considered together, the total financial cost of treating stroke is expected to increase from
the current $71.6 billion to $184.1 billion dollars spent annually on stroke care, and a large
proportion of these funds are due to rehabilitation costs[1].

II. Risk Factors for Cardiovascular Disease and Stroke
Stroke is by definition a form of total CVD, thus stroke and CVD share several risk factors
summarized below. Further, while each individual risk factor may contribute to AIS
through different pathophysiological mechanisms, each of the following AIS risk factors
has been shown to contribute to thrombus/embolus formation, vascular damage,
endothelial

dysfunction,

atherosclerosis,

and

chronic

inflammation.

Additional

mechanisms may be noted under each individual risk factor, in addition to these common
mechanisms. The role of inflammation in AIS will be discussed in more detail later in this
document.
Race/Ethnicity
There are differences in both AIS prevalence and mortality rate among different ethnic
groups. Specifically, AIS prevalence is higher among blacks and Hispanics compared to
whites, and AIS mortality rate is highest among blacks compared to all other ethnic
groups[1]. The differences between ethnic groups is likely due to an unequal distribution
of CVD risk factors and socioeconomic status among the groups.
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Gender
Women have a higher overall lifetime risk of AIS than men[1]. Further, in 2014, the
American Heart Association released specific guidelines for treating AIS in women that
addressed several AIS risk factors that are specific to women, as well as discussed
common risk factors that are more prevalent in women than men[2]. Both oral
contraceptive use and preeclampsia during pregnancy have been show to increase AIS
risk in women[2]. Interestingly, atrial fibrillation, an AIS risk factor common to both women
and men, has been shown to confer a greater risk of AIS in women than in men[2].
Hypertension
Hypertension has been shown to be the strongest predictor of future AIS for all AIS
subtypes[3]. Individuals with a BP greater than 140/90 have 2-4 times greater AIS risk
than individuals with a BP ≤ 120/80[1]. Further, antihypertensive medications have been
shown to dramatically reduce AIS risk, and administration of antihypertensive medications
following AIS reduces the risk of recurrent stroke in AIS patients[1].
Diabetes Mellitus
Individuals with increased blood glucose levels above normal are at nearly double the risk
of AIS than individuals with normal glucose levels[1]. Further, the risk of AIS in individuals
with uncontrolled diabetes is 3-fold higher than normal[1]. Lastly, controlling blood
glucose, both acutely and after discharge following AIS, has been shown to reduce AIS
severity and improve functional outcomes[1].
Atrial Fibrillation
After hypertension, atrial fibrillation (AF) is the second most common risk factor for AIS.
AF is a condition characterized by an abnormal heart rhythm that occurs when the atria
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of the heart do not fully contract or fibrillate. This failure to contract does not allow the
entire volume of blood contained in the atria to flow into the ventricles. In chronic AF, the
atria fibrillate for extended periods of time causing blood to pool in the atria, which may
eventually clot and be ejected into the bloodstream. Incidence of AIS in individuals with
AF is nearly five times higher than normal[1].
Psychosocial Risk Factors
Recently, there has been an influx of data to suggest a relationship between
psychological status and AIS risk. Specifically, generalized anxiety, depression, and other
mood disorders are associated with an increased risk of AIS[1]. Further, depression is
more common among AIS survivors, independent of AIS severity and disability following
AIS[4].
In the Atherosclerosis Risk in Communities study (ARIC), multivariate analysis
showed that age, smoking, systolic blood pressure, and diabetes mellitus were
independent risk factors for all ischemic stroke subtypes[3]. Diabetes and smoking were
important predictors of lacunar and non-lacunar ischemic stroke, and the risk appears to
be slightly higher for lacunar compared to non-lacunar AIS[3]. The results of the ARIC
study suggest that the etiologic relationship of risk factors with ischemic stroke varies by
subtype; however, the molecular mechanisms giving rise to differences in AIS subtype
risk are unclear.

III. Types of Stroke
Stroke can be broadly classified into two subtypes: acute ischemic stroke (AIS) and
hemorrhagic stroke. AIS makes up approximately 87 percent of total strokes, and as
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discussed previously, the prevalence of AIS is expected to increase over the next 20
years, whereas prevalence and mortality rates associated with hemorrhagic stroke have
been relatively stable in past years and no increases are expected in the near future. The
focus of this dissertation is solely on AIS, and hemorrhagic stroke will not be discussed
in detail; however, while the pathophysiology of AIS and hemorrhagic stroke differ, the
functional deficits among stroke survivors are similar.
AIS can be further defined into more narrow subtypes based on AIS etiology, and
a system of classification has been developed for the Trial of Org 10172 in Acute Stroke
Treatment (TOAST)[5]. The TOAST classification identified five AIS subtypes
summarized below:

(1) Large-Artery Atherosclerosis (Thrombus/Embolus)
•

Defined by imaging of at least 50 percent stenosis of intra- or extra cranial vessel[5]

•

Represents ~ 27 percent of diagnosed AIS cases[6]

(2) Cardioembolic
•

Risk factors include AF or other arrhythmias, valvular disease, prosthetic valves,
myocardial infarction (MI)[5]

•

Represents the largest proportion of determined AIS cases – 40 percent[6]

(3) Small-Vessel or Lacunar
•

Lacunar AIS is an occlusion of penetrating vessels that supply deep brain regions.
CT or MRI to confirm ischemic territory is indicative of lacunar AIS[5].

•

Represents 25 percent of determined AIS cases[6]
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(4) Other Determined Cause – Probable- 4 percent of determined AIS cases[6]
(5) Unknown – Cryptogenic – 52 percent of all AIS cases[6]

The TOAST classification is the most commonly used AIS subtype classification used in
the US, however, there are other subtype classification systems, such as the Causative
Classification System (CCS) and the Chinese Ischemic Stroke Subclassification system
(CISS), that are used to determine AIS etiology as well[7].

IV. Current Treatments for Ischemic Stroke
For decades, tissue plasminogen activator (tPA) has been the only pharmacological
thrombolytic agent available for the acute treatment of AIS and is considered the “gold
standard” in AIS care[8]. Unfortunately, given intravenously, tPA achieved recanalization
that leads to an improvement in AIS severity and functional outcome in only 15 percent
of patients [8]. Further, due to several contraindications, only 4 percent of patients are
eligible to receive intravenous tPA. Arguably, the largest limitation is the narrow time
window for treatment, 4.5 hours following AIS symptom onset, that intravenous tPA has
been shown to be safe and effective[8]. Recently, intra-arterial tPA has been approved
for use in AIS for up to 5.5 hours after AIS symptom onset, and while intra-arterial tPA
administration has been shown to be slightly more effective than intravenous tPA
administration, intra-arterial tPA is also only effective in a small number of eligible
patients[8]. Aside from tPA, mechanical clot retrieval has also been a therapeutic option
in AIS. Recently in 2015, the results of several clinical trials evaluating the use of
mechanical retrieval devices alone or in combination with intra-arterial tPA have led to a
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reevaluation of the gold standard of AIS care. In the Multicenter Randomized Clinical Trial
of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN),
mechanical retrieval and tPA administration within 6 hours of AIS symptom onset resulted
in improvements in severity and outcome that were greater than those seen with
intravenous or intra-arterial tPA alone[9]. While the ability to utilize mechanical retrieval
devices is limited by several factors, including clot location, eligible patients exhibit
profound improvements compared to prior treatment strategies[10]. In addition to the
thrombolytic approaches recently discussed, there has been a large number of drugs that
have shown therapeutic efficacy in pre-clinical models of AIS. These drugs have a wide
range of actions that may aid in neuroprotection, both acutely and chronically following
AIS; however, most, if not all of these drugs failed in clinical trials. A summary of the most
recent clinical trials in AIS and their results is summarized in Table 1.1.

V. Ischemic Stroke Pathophysiology
Regardless of AIS subtype, the pathophysiological mechanisms that result in brain
damage are similar. Briefly, AIS is defined by a lack of blood flow to the brain, commonly
due to a clot impeding blood flow in a vessel responsible for supplying blood to the brain.
Reduced oxygen delivery results in brain cell death in the immediate and surrounding
areas supplied by the occluded vessel. The brain is supplied by two main blood vessels:
the internal carotid arteries (ICA) and the vertebral arteries. The internal carotid arteries
arise as a branch of the common carotid artery in the neck and supply the anterior portion
of the brain. Specifically, the ICA branches into two large branches, the anterior (ACA)
and middle cerebral arteries (MCA), and these vessels supply the entire frontal cortex, as
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well as regions of the temporal and parietal cortices. The ACA and MCA further branch
into smaller vessels that penetrate the cortex to supply deep brain structures, such as the
basal ganglia and thalamus. The basilar artery is formed by the joining of the vertebral
arteries, and the basilar artery branches once inside the skull to supply the posterior
portion of the brain. Specifically, the basilar artery branches into the posterior cerebral
arteries (PCA) to complete the Circle of Willis formed by the ACA, MCA, and
communicating arteries (Figure 1.2). The basilar artery supplies the pons and brainstem,
and the PCA supplies the posterior cerebral cortex and branches to supply the midbrain
and cerebellum[11].
The specific vessel occluded in AIS will determine the distinct symptoms and
degree of symptoms manifested in AIS. Approximately 70 percent of AIS are the result of
occlusion of the anterior circulation (ACA and MCA), and the MCA and its branches are
the most commonly occluded vessels in AIS. Further, because the MCA and branches
are responsible for supplying blood to nearly 50 percent of the brain, a large region of
brain is susceptible to cell death due to ischemia (Figure 1.3). Because the MCA supplies
the broadest area of the cerebral cortex, AIS symptoms resulting from an occlusion of the
MCA can be numerous and vary greatly.
The brain is one of the most metabolically active and demanding organs in the
body, and this is reflected by the fact that while the brain is only 2 percent of total body
weight, it accounts for roughly 20 percent of the body’s total oxygen consumption. Further,
an average weight brain requires an oxygen consumption rate of 49 mL O2/min to
maintain the energetic requirements required for normal brain function. This oxygen is
predominantly utilized in combination with glucose to produce adenosine triphosphate
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(ATP). Both oxygen and glucose are delivered to the brain via the blood and total cerebral
blood flow (CBF) must remain relatively constant at a rate of 798 mL/min[12].
During AIS, the ischemic area has two distinct regions: the infarct core and
penumbra. The infarct core is the center of the ischemic area in the immediate territory of
the occluded blood vessel, and CBF in this region falls to <10-12 mL/min. The penumbra
surrounds the infarct core, and due to increased blood supply from collateral vessels,
continues to receive slightly more CBF at a rate of 18-20 mL/min. Due to the dramatic
reduction in CBF at the infarct core, neurons and glial cells in this area will begin to die
within minutes of ischemic onset, and cells in the penumbra can only survive 1-2 hours if
CBF is not restored[13].
If CBF is not rapidly restored, the ischemic cascade is activated, which is depicted
in Figure 1.4. Cells in the ischemic area deplete local O2 and glucose stores and can no
longer produce the amount of ATP required to function. The cells in this area then shift to
anaerobic metabolism, resulting in the production of toxic bi-products, such as lactic acid,
that directly damage neurons. Further, ATP depletion causes cells to fail to maintain ionic
balance through channels such as the sodium/potassium pump. This induces cell death
through several mechanisms, including cellular edema and excessive calcium influx,
which triggers excessive neurotransmitter release or excitotoxicity, reactive oxygen
species generation by mitochondria, and activation of apoptosis via mitochondrialdependent and independent mechanisms[13].
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VI. The Immune Response and Ischemic Stroke
Dead and dying brain cells release signals that activate both the innate and
adaptive arms of the immune system following AIS, and the immune system plays a
critical role in the resolution of ischemia and ischemic damage. Under normal
circumstances, the brain and CNS are considered to be “immune privileged”, as the CNS
is kept sequestered from the immune mediators present in the periphery through
maintenance of the blood-brain barrier (BBB). Brain endothelial cells, joined by tight
junctions that create a barrier that is highly selective of the molecules that can enter the
brain, form the BBB. Further, glial cells, specifically astrocytes, surround the endothelial
cells of the BBB and provide trophic support to endothelial cells. Following stroke, both
the endothelial cells and astrocytes are susceptible to death through ischemia and as
these cells begin to die, the BBB becomes more permeable and the CNS becomes more
exposed to the peripheral immune response. Further, reactive oxygen species generation
and local immune signals in the CNS can promote BBB breakdown. The loss of BBB
integrity allows for both peripheral immune cells and immune mediators, such as
cytokines and chemokines, to more freely enter the brain to elicit a response. While a
degree of immune cell infiltration into the brain is crucial for AIS recovery, the distribution
and total amount of immune cells entering the CNS can result in both beneficial and
harmful effects on AIS outcome. The innate and adaptive immune responses are
summarized below, with regard to their role in AIS recovery. Figure 1.4 also summarizes
ischemic cascade following AIS.
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Innate Immune Response to AIS
The innate immune response is a rapid, non-specific response that protects the body from
pathogens, termed inflammation. Thus, the cells of the innate immune arm are the first to
respond and/or migrate into the brain following AIS. Neutrophils are the predominant cell
type of the innate arm and are also the most abundant circulating leukocyte in
humans[14]. Neutrophils are responsible for phagocytosis and killing of microorganisms,
and to accomplish these functions, neutrophils possess secretory granules that are
released upon neutrophil activation. Dying brain cells release signals, danger-associated
molecular patterns (DAMPS) that bind to receptors on neutrophils to induce their
activation. Upon activation, neutrophils release their secretory granules that contain
several enzymes, the most abundant of which is matrix metalloproteinase 9 (MMP9), but
also contain several cytokines and chemokines including pro-inflammatory, tumor
necrosis factor related apoptosis inducing ligand (TRAIL), and anti-inflammatory cytokine
transforming growth factor beta (TGFβ)[14]. Neutrophil subtypes have been identified in
animal studies based on their propensity to either promote or inhibit inflammation;
however, no neutrophil subtypes have been identified in humans. It is important to note
that arginase 1 (ARG1) mRNA expression was used as the sole marker to define proinflammatory neutrophils in animals[15].
Because of the dualistic role of neutrophils in promoting and inhibiting
inflammation, the question of whether neutrophils play a beneficial or harmful role
following AIS remains, and there is evidence to support both roles. Implicating neutrophils
as harmful following AIS is the correlation between the time of neutrophil migration into
the brain and the subsequent increase in infract size following AIS[14]. Further, in a rodent

11

AIS model, administration of anti-neutrophil serum reduced infarct size following middle
cerebral artery occlusion (MCAO)[16]. There is also evidence to suggest that neutrophil
accumulation in the brain may directly block microvessel circulation, reducing collateral
blood flow to the infarct, providing a functional mechanism of decreased infarct size as
the result of reduced neutrophil infiltration into the brain [16]. To this end, several clinical
trials were designed to prevent neutrophil infiltration into the brain following AIS. AIS
patients in the Enlimomab Acute Stroke trial treatment group were given Enlimomab, an
anti-ICAM1 antibody, which had been previously shown to decrease infarct size and
reduce neutrophil infiltration into the brain in animal models of AIS. In this trial, patients
treated with Enlimomab had no reductions in infarct size and patients displayed worse
functional outcomes compared to the placebo group[17]. These conflicting results
between animal models of AIS and human clinical trials demonstrate the complicated role
of neutrophils in AIS and warrant further investigation.
Adaptive Immune Response to AIS
One of the main functions of the innate arm of the immune response is to activate the
adaptive immune response. In contrast to inflammation, the adaptive immune response
is directed at a specific antigen and confers a more direct resolution than innate
inflammation. T and B-lymphocytes are the predominant cells of the adaptive immune
response[18], and while both have been implicated in AIS, the remainder of this section
will focus on the role of T lymphocytes in AIS (Figure 1.5).
Prior to initiating an immune response, T cells must be activated by an antigenpresenting cell (APC). Once an APC has bound an antigen, the APC presents the antigen
to the T cell, activates the T cell through costimulation via membrane bound receptors,
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and activated T cells can then rapidly divide and secrete cytokines to elicit an antigenspecific immune response. The two receptors/signals required for T cell activation are:
the T cell receptor, CD3, located on the T cell membrane, and a costimulatory molecule
on the surface of the APC, typically CD28[18].
Overall, lymphocytes enter the brain roughly 1-7 days following AIS[18]; however,
there are several different T lymphocyte subsets, and each lymphocyte subset has a
distinct role following AIS, which is summarized below.
Helper T Lymphocytes
Helper T lymphocytes, generally referred to as CD4+ T cells, activate other T lymphocyte
subsets, specifically cytotoxic CD8+ T cells, and other immune cells[18]. CD4+ T cells
can be further broken into several subtypes, including TH1, TH2, and TH17 helper T cells,
based on the cytokines each subset secretes upon activation. TH1 cells are considered
pro-inflammatory in nature, as interferon gamma (IFNy) is their most abundantly secreted
cytokine mediator. IFNy has been shown to contribute to increased infarct volume in
animal models of AIS, and increased IFNy levels are seen in human AIS patients and
positively correlate with AIS severity. TH2 helper T cells are considered anti-inflammatory
in nature, as their primary cytokine effectors are interleukin-4 (IL4) and IL-10 have been
shown to have a protective effect in animal models of AIS[19, 20]. TH17 are distinct from
TH1 and TH2 helper T cells and are named for their primary cytokine effector, IL-17. IL-17
has been shown to exacerbate damage in the late phase (3-7 days) following AIS[21].
Further, IL-17 can activate other pro-inflammatory immune cells, such as ϒδ T
Lymphocytes that will further increase IL-17 following AIS[22].
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ϒδ T Lymphocytes
ϒδ T Lymphocytes are considered a hybrid between an innate and adaptive immune cell,
given their ability to bind DAMPs to mediate non-specific inflammation, as well as an
antigen-specific response. As mentioned previously, ϒδ T Lymphocytes secrete IL-17
and like TH17 cells have been shown to exacerbate damage following AIS[22]. Further,
production of IL17A has been shown to increase damage following AIS through increased
neutrophil recruitment to the brain, and administration of anti-IL17A dramatically reduces
infarct volume in an animal model of AIS, in part due to reduced neutrophil infiltration into
the brain[22].
Cytotoxic T Lymphocytes
Cytotoxic T lymphocytes, generally referred to as CD8+ killer T cells, are the predominant
effector T cell subset. Upon activation, CD8+ cells release cytotoxic enzymes to initiate
apoptosis in infected or compromised cells. CD8+ cells are generally considered to be
the primary T lymphocyte subset responsible for the detrimental effect T lymphocytes
appear to have following AIS[23]. In support of this, mice depleted of CD8+ t cells have a
dramatic reduction in infarct volume following AIS compared to wild type[23].
Regulatory T Lymphocytes
Regulatory T lymphocytes (TREG) are considered anti-inflammatory in nature due to the
production of IL-10 and TGFβ, and function to inhibit other immune cells, predominantly
cytotoxic CD8+ T cells, to prevent autoimmune responses[24]. Because of the detrimental
role of CD8+ T cells in AIS, the response of TREG cells has been implicated as a protective
mechanism following AIS[24]; however, there is also conflicting evidence to suggest that
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TREG cells may have a detrimental effect following stroke by inducing cerebral
microvasculature dysfunction[25].
Human Biomarker Studies
There has been an abundant amount of research focused on identifying biomarkers of
AIS in human patients. Gene expression or mRNA expression in the peripheral blood of
AIS patients can be used to peripherally monitor the immune response to AIS, as changes
in gene expression measured in the whole blood are the result of altered gene expression
in leukocytes[26]. Microarray technology allows for the analysis of total mRNA in patient
whole blood and cerebrospinal fluid, providing insight into the gene expression changes
related to the immune response to AIS. Not only can these changes in gene expression
be used to identify leukocyte subsets that are up-regulated in blood, but also the effector
genes that characterize the immune response mounted by total leukocytes. There have
been several studies, by our laboratory and others, measuring gene expression in human
AIS patients within 24 hours of symptom onset[27, 28]. These studies have identified
immune-related genes that are significantly altered in AIS compared to control, that may
represent novel therapeutic targets in AIS (Figure 1.6). Further, these gene expression
changes have been examined in regards to the particular leukocyte subset responsible
for the alteration seen in whole blood and have demonstrated that changes in gene
expression in whole blood are mainly attributed to neutrophils and monocytes following
AIS[27] (Figure 1.7). These studies provide insight into the immune response to AIS in
human patients that may be translated for testing in animal models of AIS.
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Post-Stroke Immunosuppression
While AIS induces a local immune response in the brain, AIS also has a profound impact
on systemic immunity. Within days of AIS, many AIS patients develop immunodepression,
characterized by decreased total lymphocyte counts, splenic atrophy, and increased antiinflammatory

cytokine

immunosuppression[29].
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immunosuppression are unclear, the degree of immune suppression can greatly impact
AIS recovery, as approximately 40 percent of AIS patients experience a secondary
infection, commonly pneumonia or urinary tract infection, following AIS[30]. These
secondary infections are associated with increased mortality and poor outcome following
AIS, independent of initial AIS severity and infarct volume. The evolutionary purpose of
post-stroke immunosuppression is unclear, however, it has been speculated that this
response may originate in the brain to limit the autoimmune response in the brain in the
delayed phase of AIS. While this may serve to limit autoimmune damage in the brain, it
may also be detrimental by increasing risk of infection, and an immune balance must be
maintained following AIS for ideal recovery[29]. As previously mentioned, post-stroke is
characterized by lymphocytopenia; however, there have been no human studies that
address the alterations of specific leukocyte subsets following AIS. In addition to total
lymphocyte count, the overall function and lymphocyte activity following AIS. In one study
in human AIS patients, while lymphocytopenia was observed following AIS, the remaining
lymphocytes possessed normal functional activity[31]; however, there have been other
studies that have shown a down-regulation of both CD3 and CD28, indicating decreased
activation and function of peripheral T lymphocytes. Given the conflicting findings, the
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mechanisms mediating post-stroke immunosuppression remain unknown and warrant
further investigation, but may offer a novel therapeutic strategy to reduce infection rate
and increased secondary mortality in AIS patients.
Inflammation and Risk of AIS
In addition to the immune response following AIS, immune function and general
inflammation can contribute to increased risk for AIS[32]. CV risk factors, such as
hypertension, atherosclerosis, and obesity, are associated with chronic inflammation and
immune dysregulation, which in addition to vascular dysfunction may contribute to their
role in increased AIS risk[33]. Further, medications to reduce CV risk factors, such as
anti-hypertensives or statins, are commonly prescribed following AIS and have been
shown to improve AIS outcome. It is likely that these improvements in recovery may be
due, in part, to reductions in inflammation or other beneficial effects on immune function
attributed to remediation of AIS risk factors. Systemic infections, both bacterial and viral,
occur in a large percentage of AIS within two weeks of AIS onset, indicating that infections
may confer a higher risk of AIS[32]. Overall, alterations in immune function prior to AIS
likely contribute to the immune response following AIS.
Clinical Trials Targeting the Immune Response in AIS
While several cell-based approaches and pharmacological therapeutics directly targeting
the immune system have shown efficacy in reducing AIS severity in animal models of
AIS, none of these approaches has shown efficacy in human clinical trials[34]. The most
recently completed clinical trials targeting the immune response in AIS are summarized
in Table 1.1. Given the differences between the immune systems of humans and
animals[35], therapeutic interventions based on animal studies have failed to translate to
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the human population, and overcoming this translational gap will be crucial to targeting
the immune system in AIS.

VII. Neutrophil-Lymphocyte Ratio in Ischemic Stroke
The neutrophil-lymphocyte ratio (NLR) has been established as a marker of systemic
inflammation and may also indicate the balance between innate and adaptive immune
responses occurring systemically[36]. The NLR is calculated by dividing the total
peripheral neutrophil count by the total peripheral leukocyte count. The NLR is currently
used clinically in a wide variety of cancers to predict prognosis, tumor metastasis, and
response to chemotherapy, and an elevated NLR is indicative of poor outcome on all
measures[36]. While the NLR is not currently used in AIS clinical care, there is evidence
to suggest that the NLR may be a useful prognostic biomarker of AIS severity and
outcome. Specifically, our lab and others have shown that an NLR>5, independent of
infarct volume, is associated with increased 60 day mortality [37, 38] and worse 90 day
outcome, as assessed by the Modified Rankin Score (MRS)[39]. Further, in addition to
the NLR, total neutrophil count was positively correlated with increased mortality, whereas
total lymphocyte count was negatively correlated with mortality, suggesting a harmful role
for neutrophils and a protective role of lymphocytes in AIS[38]. Further research is needed
to determine the physiological mechanisms responsible for modulating the NLR following
stroke; however, the NLR may be currently implemented in AIS clinical care and may offer
additional insight into stratifying AIS patients into treatment groups or predicting outcome.
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VIII. Arginase
Arginase (ARG) is an enzyme that catalyzes the conversion of the semi-essential amino
acid L-arginine to L-ornithine and urea (Figure 8) [40]. This reaction is the final step of the
urea cycle to rid the body of excess nitrogen/ammonia through detoxification into
urea[40]. ARG exists as two isoforms, encoded by distinct genes on separate
chromosomes: ARG1 and ARG2[40]. ARG1 is the more abundant ARG isoform, located
in the cytoplasm, and expressed primarily in the liver, and ARG2 is located within
mitochondria mainly in the kidneys; however, both isoforms, particularly ARG1, are
expressed by various cells/tissues, including endothelial cells, vascular smooth muscle
cells, and leukocytes[41]. Constitutive expression of ARG, in both animals and humans,
is summarized in Table 1.3. ARG gene expression can be stimulated by various stimuli,
including pro-inflammatory cytokines, oxidized LDL cholesterol, glucose, angiotensin II,
and hypoxia. ARG activity can also be increased in response to these stimuli,
independent of changes in gene expression, and also by post-translational modifications,
such as S-nitrosylation by NO[41].

IX. Arginase 1 and Vascular Function
As mentioned previously, both endothelial and vascular smooth muscle cells express
ARG1, suggesting a role for ARG1 in regulating vascular tone/function. L-arginine is a
common substrate for both ARG1 and nitric oxide synthase (NOS)[41]. NOS is
responsible for the production of NO, originally named “endothelium-derived relaxing
factor”. NO is a gaseous free radical, a signaling molecule that can freely diffuse across
cellular membranes to elicit an action. As it’s original name would suggest, NO plays a
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crucial role in vasodilation. Vascular endothelial cells use NO to signal to and induce
relaxation in adjacent vascular smooth muscle cells, resulting in vasodilation and
increased blood flow[41]. Because both vascular endothelial cells and smooth muscle
cells express ARG1, excessive ARG1 can compete with NOS for L-arginine, resulting in
impaired NO production and vascular dysfunction. Direct comparison of the Km values
would suggest that the high Km of ARG1 (1-20 mM) compared to the Km of NOS (1-5 uM)
should not allow for effective competition between these enzymes[42]. However, while
the Km value of ARG1 is much higher than NOS, the rate of catalysis of ARG1 is much
higher than NOS, thus when L-arginine concentrations are high enough to exceed the Km
of ARG1, ARG1 activity exceeds NOS activity. ARG1 has been implicated in the “arginine
paradox”, a phenomenon where increased extracellular L-arginine is required to elicit NO
production by endothelial NOS (eNOS), despite the fact that cytosolic concentrations of
L-arginine are well above the Km of eNOS. In addition to urea and L-ornithine, proline,
and purines are also products of the L-arginine reaction, and these products promote both
collagen synthesis and vascular smooth muscle cell hypertrophy, providing another
mechanism by which ARG1 contributes to vascular dysfunction and arterial stiffness,
independent of NOS[42].
Given the role of ARG1 in mediating vascular function, the role of ARG1 has been
investigated in the development of CVD. Increased ARG1 expression and activity is
associated with several CV risk factors, including hypertension, atherosclerosis, and
diabetes, and ARG inhibition has been shown to improve CV function in both
experimental and clinical studies (Table 1.3)[41].
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X. Vascular Function and Ischemic Stroke
There are several non-invasive assessments used to measure the structure and function
of vasculature in human subjects, including carotid-intima medial thickness (cIMT) and
pulse wave velocity (PWV). IMT refers to the measurement of the thickness of the
innermost layers of the arterial wall: the tunica intima and tunica media. Increased cIMT
can result from arterial remodeling, such as increased extracellular matrix synthesis and
vascular smooth muscle cell hypertrophy, and several CV risk factors, including
atherosclerosis, diabetes, and hypertension are associated with increased cIMT[43].
Common carotid artery (CCA) IMT has been consistently identified as significant predictor
of AIS risk[43]. CCA IMT values ≤ 0.87 mm are not associated with an increased risk of
stroke; however, an increase in CCA IMT by 0.20 mm is associated with a 33 percent
increase in AIS risk[44]. Further, CCA IMT appears to be most predictive of the largeartery AIS subtype, likely due to the strong association between cIMT and presence of
atherosclerosis[45]. While cIMT provides a measure of vessel wall thickness, it is not a
direct assessment of arterial stiffness; however, there is a strong correlation between
cIMT and PWV. Carotid-femoral PWV (cfPWV) is considered to be a measure of aortic
arterial stiffness, and increased cfPWV is associated with an increased risk of AIS[45].
Further, not only is cfPWV higher in AIS compared to control subjects, but cfPWV in AIS
patients appears to be highest among lacunar AIS cases[45]. In addition, cfPWV is
positively associated with several pro-inflammatory biomarkers, including C-reactive
protein, TNFa, and IL-6[46]; however, it is unclear whether these inflammatory factors
directly induce increases in cfPWV or indirectly through CV risk factors that are
associated with an increase in cfPWV. Lastly, while cfPWV is considered a measure of
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aortic stiffness, brachial-ankle PWV (baPWV) is strongly correlated with the presence and
degree of intracranial cerebral atherosclerosis[47], and thus may offer prognostic
information in context of AIS.

XII. Arginase 1 and Immune Function
In single-celled organisms, amino acid depletion, specifically L-arginine depletion, is used
to inhibit the proliferation of other single-celled organisms competing for the same
resources[48]. Similarly, it appears as metazoans utilize a similar strategy to limit
undesired expansion of proliferating cells. ARG1 is constitutively expressed by both
neutrophils and monocytes in humans and mice; however, while in mice ARG1
expression and activity can be induced by exposure to TH2 cytokines, human ARG1
expression and activity are not affected by these stimuli[48]. Circulating neutrophils and
monocytes expressing ARG1 can deplete L-arginine both locally and systemically. During
recent years, L-arginine depletion and ARG1 expression has been implicated as an
immunosuppressive pathway in the human immune system. Specifically, both L-arginine
depletion and ARG1 expression have been shown to inhibit T cell proliferation and inhibit
T-cell responses to antigen[48]. The mechanisms by which L-arginine depletion/ARG1
may regulate T-cell function are summarized in Figure 1.9 [48]; however, these
mechanisms have been described in-vitro and very little is known about the mechanisms
of immunosuppression in-vivo. The most commonly described mechanism of ARG1induced immunosuppression is downregulation of the CD3ζ chain of the T cell receptor.
CD3ζ is the main signal-transducing component of the T cell receptor, and loss of this
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molecule results in a lack of T cell proliferation, activation, and in some cases, may induce
apoptosis in these cells[48].

XIII. Arginase 1 and Ischemic Stroke
Given the relationship between ARG1 and the immune response, it is not surprising that
ARG1 plays a role in AIS; however, there are only two experimental studies directly
evaluating the role of ARG1 in an animal model of AIS. The first examined the changes
in ARG1 localization in the rat brain before and at several time points following a
photothrombotic stroke model[49]. Prior to stroke, ARG1 expression was localized to
neurons only, however from 1 day to 30 days, there is a marked upregulation of ARG1
expression, not in neurons, but in inflammatory cells, such as microglia, macrophages,
and astrocytes[49]. The second study, released in early 2015, described a mechanism of
immunosuppression following murine MCAO mediated by ARG1 release from
neutrophils[50]. The immunosuppression in this study was characterized by splenic
atrophy, lymphocytopenia, and decreased T cell proliferation[50], which is identical to the
clinical presentation of post-stroke immunosuppression in human AIS patients. To date,
there have been no experimental studies evaluating the use of an ARG inhibitor, such as
nor-NOHA, in improving outcomes and prevention of immunosuppression following
MCAO.
In humans, there have been a limited number of studies that have examined the
role of ARG1 following stroke. Two studies confirmed that ARG1 is the most significantly
upregulated gene within 24 hours of AIS compared to control subjects[27, 28]. Further,
ARG1 expression is highest in neutrophils[27], suggesting a potential role for neutrophil
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ARG1 in mediating AIS severity and immunosuppression; however, the role of ARG1 and
the immune response following AIS in humans has not been characterized.
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Mechanism and Compound
Leukocyte Adhesion Inhibition
Anti-ICAM1 antibody
HU23F2G
Neutrophil Modulation
Neutrophil Inhibitory Factor
Cytokine Inhibition
IL-1 Receptor Antagonist

Trial

Result

EAST
HALT

Adverse Effect
No Benefit

Phase II

No Benefit

Phase II

No Benefit

Table 1.1: Clinical Trials Targeting the Immune Response in Ischemic Stroke.
Adopted from Durukan et al. 2007. Pharmacology Biochemistry and Behavior.
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Background: A balanced immune system response plays an important role in acute
ischemic stroke (AIS) recovery. Our laboratory has previously identified several immunerelated genes, including Arginase 1 (ARG1), with altered expression in human AIS
patients. The neutrophil-lymphocyte ratio (NLR) may be a marker of the degree of
immune dysregulation following AIS; however, the molecular mechanisms that may
mediate the NLR are unknown. The purpose of this study was to: (1) Examine the
relationship between ARG1, NLR, and AIS severity and (2) To Utilize Principal
Component Analysis (PCA) to statistically model multiple gene expression changes
following AIS.

Methods: AIS patients and stroke-free control subjects were recruited and blood samples
were collected from AIS patients within 24 hours of stroke symptom onset. White blood
cell differentials were obtained at this time to calculate the NLR. Gene expression was
measured using real-time PCR. Principal component analysis (PCA) with varimax rotation
was used to develop composite variables consisting of a five-gene profile.

Results: ARG1 was positively correlated with NLR (r=0.57, p=0.003), neutrophil count
(r=0.526, p=0.007), NIHSS (r=0.607, p=0.001) and infarct volume (r=0.27, p= 0.051).
PCA identified three principal components that explain 84.4% of variation in the original
patient gene dataset comprised of ARG1, LY96, MMP9, s100a12, and PC1 was a
significant explanatory variable for NIHSS (p<0.001) and NLR (p=0.005).

Conclusions: Our study suggests a novel relationship between ARG1, NLR and stroke
severity, and the NLR is an under-utilized clinically available biomarker to monitor the
post-stroke immune response.
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Introduction
A balanced immune system response plays an important role in acute ischemic stroke
(AIS) recovery. [1, 2] AIS results in a well described immediate, but non-specific innate
inflammatory response. Innate inflammatory processes activate adaptive immune cells
responsible for controlling inflammation, modulating ischemic damage and promoting
neurogenesis.[3] In some patients, for reasons poorly understood, the adaptive immune
system is incapable of responding to the innate inflammatory signals, resulting in poststroke immune suppression. Stroke-induced adaptive immune suppression is associated
with greater stroke severity, increased risk of infection and poor recovery, and is
characterized by decreased T lymphocyte function, and peripheral cell counts and
increased inflammatory cytokines. [1, 4] Human stroke genomic biomarker studies have
identified a common panel of five genes responding to AIS in the peripheral blood:
Arginase 1 (ARG1), lymphocyte antigen 96 (LY96), matrix metalloproteinase 9 (MMP9),
s100 calcium binding protein A12 (s100A12), and chemokine CC motif receptor 7
(CCR7).[5, 6] Our laboratory has also shown that the neutrophil-lymphocyte ratio (NLR)
is a simple, inexpensive biomarker that may be used to predict outcome following AIS
and may be a clinically available marker of the degree of immune dysregulation following
AIS[7, 8]; however, the relationship between the NLR and these genomic biomarkers
following AIS is unknown.
ARG1 is consistently upregulated in the whole blood of AIS patients.[5, 6] The
traditional role for the enzyme ARG1 is catalyzing the metabolism of the substrate Larginine to L-ornithine and urea.[9] Because ARG1 and nitric oxide synthase (NOS) share
L-arginine as a common substrate, ARG1 can be viewed as a competitive inhibitor of
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NOS. In addition to this traditional role, ARG1, derived from innate immune cells, has
been shown to mediate the adaptive immune response.[10] In humans, ARG1 expression
is highest in neutrophils compared to other peripheral blood leukocytes,[5] and ARG1
protein released from neutrophils suppresses T lymphocyte proliferation through
downregulation of T lymphocyte CD3ζ chain.[10] Until very recently, ARG1-induced
lymphocyte suppression had not been shown in the context of AIS. Sippel et al. reported
that ARG1protein released from neutrophils induces lymphopenia in a murine model of
stroke.[11] Given the differences between murine and human immune systems, [12] it
remains to be determined whether ARG1 induces immunosuppression in human AIS
patients.
The purpose of this pilot study was to: (1) Examine the relationship between ARG1,
NLR, and AIS severity. We hypothesized that increased ARG1 expression and serum
protein activity is associated with an increased NLR, giving rise to increased AIS severity
and poor outcome. (2) To validate the role of ARG1 as a novel biomarker of immune
suppression in AIS, and (3) To Utilize Principal Component Analysis (PCA) to statistically
model multiple gene expression changes following AIS.

Materials and Methods
Subject Recruitment
Informed consent was obtained from all individual participants included in the study. AIS
patients and stroke-free control subjects were recruited from Ruby Memorial Hospital
(Morgantown, WV). Male and female AIS patients were eligible for recruitment if the
following inclusion criteria were met: (1) age ≥ 18 years, (2) confirmation of acute stroke
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by neuroimaging (CT or MRI), and (3) had blood drawn within 24 hours of symptom
onset/”last-known normal”, prior to thrombolysis or interventional treatment. Patient data
from the medical record were reviewed and recorded, including (1) National Institutes of
Health Stroke Scale (NIHSS), (2) clinical laboratory analyses, including white blood cell
differential, and (3) brain imaging (CT/ MRI). Stroke-free control subjects were eligible for
recruitment if the following inclusion criteria were met: (1) age ≥ 18 years, and (2) no
history of AIS, transient ischemic attack, brain injury, or other overt central nervous
system disease, and (3) recent hospitalization. Medical histories were obtained directly
from stroke-free control subjects; however, complete access to medical records of control
subjects was not available.

Infarct Volume Calculation
Brainlab iPlan® software was used to manually trace and calculate infarct volume from
either CT or MRI images. All images were obtained within 24 hours of symptom onset,
regardless of modality. All infarct volume calculations were verified by a neuroradiologist
at Ruby Memorial Hospital (Morgantown, WV).

Research Protocol Approval and Informed Consent
This study received approval for human subject research from the institutional review
boards of West Virginia University and Ruby Memorial Hospital (Morgantown, WV).
Written informed consent was obtained from all subjects or their authorized
representatives prior to performing study procedures.
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Blood Collection
Peripheral venous whole blood was drawn from stroke subjects no later than 24 hours of
stroke symptom onset. Blood was collected into PAXgene

Blood RNA tubes (Becton-

Dickinson). Immediately after blood collection, tubes were inverted 8-10 times and stored
at -80°C until analysis. Whole blood was collected in serum separator tubes, centrifuged
at 4000g, aliquoted into microcentrifuge tubes within one hour of collection, and stored at
-80°C until analysis.

RNA Extraction
PAXgene

Blood RNA tubes were thawed overnight (16-20 hrs) at room temperature

prior to RNA extraction. The PAXgene Blood RNA kit (Pre-Analytix) was used to
purify/extract intracellular RNA, per manufacturer’s instructions. RNA concentration and
quality was determined by absorbance using a Take3 Trio Microplate (BioTek ) read on
a Syntek Hybrid Plate Reader, and analyzed using Gen5 (BioTek) software. A260/A280
values between 1.8 and 2.2 were considered acceptable RNA quality.

Gene Expression Analysis
RNA was converted to cDNA using the High-Capacity Reverse Transcription Kit (Applied
Biosystems). cDNA (10 ng) was used for quantitative real-time PCR amplification using
SYBR Green chemistry using the Rotor-Gene Q real-time PCR cycler (Qiagen). The
following Quantitect primers (Qiagen) were used: ARG1 (NM_000045, NM_001244438),
LY96 (NM_015364), MMP9 (NM_004994), s100a12 (NM_005621), and CCR7
(NM_001838). Gene expression was normalized using both PPIB (NM_000942) and B2M
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(NM_004048). These reference genes are known to be stably expressed in whole blood
of ischemic stroke patients.[13] We confirmed that both PPIB and B2M were stably
expressed across our subject population (SD<1) (unpublished data). Fold change
differences were calculated by the ΔΔCT method.[14]

Measurement of Serum ARG1 Protein Activity
Serum ARG1 protein activity levels were determined in AIS patients using an Arginase
Activity Assay Kit (Sigma-Aldrich). All procedures were performed per manufacturer’s
instructions. Activity data is presented in units/L.

Sample Size Estimation
Post-hoc power analyses were conducted to determine achieved power, given alpha
level, sample size, and effect size using G*Power3.[15] We performed two independent
power analyses for the two primary aims of the study: (1) To evaluate the relationship of
ARG1 and stroke severity, as measured by NIHSS, and (2) To compare ARG1 expression
between stroke and control. Using a linear regression model, controlling for seven
predictors (age, sex, smoking, hypertension, hyperlipidemia, diabetes and prior stroke),
we determined that our sample size of n=26 and effect size 0.5 was sufficient to detect
differences in ARG1 expression along the NIH stroke severity score scale with 88% power
at an alpha level of 0.05. Using a linear regression model, controlling for eight predictors
(case (control v. stroke), age, sex, smoking, hypertension, hyperlipidemia, diabetes, and
prior stroke), we determined that our sample size n=45 and effect size 0.5 was sufficient
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to detect differences in ARG1 expression between stroke and controls with 99% power
at an alpha level of 0.05.

Statistical Analysis
The Mann-Whitney U test was used for testing differences between cases and controls
for continuous variables. The Fisher’s exact test was used to compare cases and control
for categorical variables. Spearman’s correlation, using the transformed variables, with a
continuity correction was used for continuous variable bivariate relationships.
If the variable’s skew was greater than 0.5 the variable was transformed using the
Box-Cox Transformation (Box & Cox, 1964). If there were negative values, we used the
exponential transformation (Manly, 1976). The application of the Box-Cox and
exponential transformations provided substantial reductions in variable skew and hence
mitigated the presence of variable specific outliers. All variables were scaled by their
standard deviation prior to applying any transformation.
Principal component analysis (PCA) with varimax rotation was used to develop
composite variables consisting of a five-gene profile. The relevant components were
chosen such that at least 80% of the original variation in the data was explained.
Following the identification of the principal components, principal component regression
was performed to assess the relationship between the derived components and the
outcomes of interest.
Linear regression model selection used Akaike information criterion (AIC)
backwards, stepwise selection to identify informative variables from among the set of
candidate regressors (age, sex, smoking, hypertension, hyperlipidemia, diabetes and

48

prior stroke). All statistical analyses were performed using the R software environment
for statistical computing and graphics. Statistical significance was taken at the 5% alpha
level.

Results
Clinical Characteristics
Forty-five subjects (26 ischemic stroke patients and 19 control subjects) were recruited
for this study. All stroke patients were confirmed definite ischemic stroke by neuroimaging
(CT or MRI).[16] There was no difference in gender between the groups; however, stroke
patients were significantly older (p< 0.001). Hypertension (p=0.007) and smoking
(p=0.014) were more common in the stroke group compared to controls. The mean
NIHSS score of the stroke patients at baseline (<24 hrs. after symptom onset) was 8.65
(range 0-28, SD=7.26). Of the 26 strokes, 11 were mild (42%), 6 were moderate (23%),
and 9 were scored as severe (35%). Ten stroke patients (38%) received rTPA; however,
all patients had blood drawn prior to rTPA administration or other intervention. The mean
time from symptom onset/”last known normal” was 7 hours and 30 min (Table 1).

ARG1 mRNA Expression, NLR and Stroke Severity
Stroke severity was analyzed as both NIHSS and infarct volume. ARG1 was positively
correlated with NLR (r=0.57, p=0.003), neutrophil count (r=0.526, p=0.007), NIHSS
(r=0.607, p=0.001) and infarct volume (r=0.27, p= 0.051) (Figure 1). Although the NLR
increases as the NIHSS increases, this was not statistically significant (p-value=0.263).
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In contrast to the NIHSS, NLR was positively correlated with infarct volume (r=0.35, p=
0.002).
Of the 5 genes in our panel, ARG1 was the only gene that was significantly
correlated with NIHSS (r=0.708, p<0.001). While the other four genes were not
significantly correlated with NIHSS, several of the genes were significantly correlated with
ARG1 expression. Both LY96 (r=0.3, p= 0.048) and MMP9 (r=0.646, p< 0.001)
expression were positively correlated with ARG1 expression. CCR7 expression was
negatively correlated with ARG1 (r=-0.381, p= 0.011).
After AIC model selection there was a statistically significant association between
ARG1 and NLR (p=0.019), adjusted for age, hypertension, and diabetes. There was also
a statistically significant relationship between ARG1 and NIHSS (p=0.001), adjusting for
age, sex, diabetes, prior stroke, and heart disease. After accounting for the adjusting
variables, ARG1 explains 74.19% of the variation in the reported NIHSS scale. Adjusting
for prior stroke, there was also a moderate relationship between the NLR and NIHSS
(p=0.078). The median NLR was slightly higher in the moderate/severe stroke patients
compared to mild, but not statistically significant (Mean NLR mild = 3.3, NLR
moderate/severe=4.5).
Prior to adjusting for regressors, there was not a statistically significant relationship
between NLR and infarct volume (r=0.347, p=0.082). Although a regression model
including all regressors suggested a statistically significant association between NLR and
infarct volume (p=0.022), the AIC selected model with only NLR (p= 0.006) and smoking
status (p=0.003) explained most of the variation in the infarct volume (Adjusted R2 full
model = 0.332 versus Adjusted R2 AIC selected model = 0.458). After accounting for the
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smoking status of the patient, NLR explains a further 29.2% of the variation in infarct
volume. When adjusting for all regressors, there was no statistically significant
relationship between ARG1 and infarct volume (p=0.627); this result held in the AIC
selected model.

Serum ARG1 Protein Activity, NLR and Stroke Severity
Serum ARG1 protein activity is significantly correlated with whole blood ARG1 mRNA
expression (r= 0.502, P=0.11). Similar to ARG1 mRNA, there is a significant relationship
between serum ARG1 protein activity and stroke severity, as measured by NIHSS. There
is a moderately significant unadjusted relationship between serum ARG1 protein activity
and NIHSS (p =0.15) (Figure 2). After adjusting for age, hypertension, smoking, heart
disease, sex, hyperlipidemia, and diabetes, we observe that serum ARG1 activity has a
statistically significant association with NIHSS (p=0.027). After AIC model selection there
was a statistically significant association between serum ARG1 protein activity and
NIHSS (p=0.005), adjusted for heart disease and prior stroke.
There is a statistically significant positive correlation between serum ARG1 protein
activity and NLR (p =0.01) (Figure 2). After adjusting for confounders, a moderately
significant relationship between serum ARG1 activity and NLR remains (p=0.062). After
AIC model selection, adjusting for age, hypertension, and diabetes, there is a statistically
significant relationship between serum ARG1 activity and NLR (p=0.009).

Gene Profile Validation in Stroke vs. Control
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Relative mRNA expression of ARG1, MMP, and s100a12 was significantly increased in
whole blood of stroke patients within 24 hours of symptom onset compared to control
(Relative ARG1 expression = 3.4 ± 3.2, p= 0.004; Relative MMP9 expression =3.2 ±2.8,
p = 0.004: Relative s100a12 expression =2.2 ±1.5, p = 0.006). Relative mRNA expression
of CCR7 was significantly decreased in whole blood of stroke patients within 24 hours of
symptom onset compared to control (Relative CCR7 expression = 0.4 ± 0.32, p= 0.03).
There was no significant difference in relative mRNA expression of LY96 between stroke
and control (Figure 3). After AIC model selection ARG1 mRNA expression remained
significantly higher in stroke compared to control (p=0.001), adjusting for sex, diabetes,
and prior stroke.

Principal Component Analysis (PCA) and Principal Component Regression (PCR)
PCA with varimax rotation identified three principal components that explain 84.4% of
variation in the original patient gene dataset comprised of ARG1, LY96, MMP9, s100a12,
and CCR7 (Table 2). With ARG1 and MMP9 featuring large positive loadings, and a large
negative loading for CCR7, the first principal component (PC) can be considered a
weighted contrast between ARG1 and MMP9 against CCR7; it explains 38.7% of total
variance (Table 2). The second PC is interpreted as a weighted average of LY96 and
CCR7 and explains 24.4% of the variation. The third PC is dominated by s100a12 and
is interpreted as the contribution of s100a12 explaining 21.3% of the variation.
Principal component regression (PCR) was performed using the first three
components and each outcome of interest: stroke versus control (non-stroke), NIHSS
score, NLR, and infarct volume. Each PCR used all three of the derived components as
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regressors. The first PC was statistically significant in the PCR models with stroke versus
control (p=0.002), NIHSS (p<0.001) and NLR (p=0.005); it had moderate explanatory
utility for infarct volume (p=0.062). The second component was statistically significant in
the PCR models with stroke versus control (p=0.012) and infarct volume (p=0.043). The
third component was not statistically significant in any of the four PCR models.

Discussion
The primary purpose of this study was to examine the relationship between ARG1, AIS
severity, and immune status as measured by the NLR. We hypothesized that increased
ARG1 expression is associated with greater AIS severity and immune dysfunction, as
measured by an increased NLR.
This is the first report of a relationship between ARG1 and AIS severity. This study
is the first to build upon existing literature which has shown that ARG1 mRNA expression
is increased in the peripheral blood, specifically by neutrophils, of AIS patients compared
to control subjects; however, the association between ARG1 and increased severity had
not yet been examined in the context of AIS. In support of our hypothesis, we observed
a statistically significant relationship between increased ARG1, both at the gene and
serum protein level, and increased AIS severity, as measured by both NIHSS and infarct
volume.
In addition to the relationship between ARG1 expression and AIS severity, we also
demonstrate a novel relationship between ARG1 expression and NLR. Here we report
that increased ARG1 expression, at both the gene and serum protein level, is positively
correlated with NLR and an increased neutrophil count. These associations were
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expected given the previous finding that ARG1 mRNA expression is highest in the
neutrophil fraction compared to other leukocyte populations.[5] Surprisingly, we report no
relationship between ARG1 expression and lymphocyte count. It has been demonstrated
previously that ARG1 protein released from neutrophils suppresses lymphocyte
proliferation both in a human ex-vivo model[10], as well as a murine AIS model.[11] Our
results indicate that changes in ARG1 expression do not result in significant changes in
lymphocyte count. This finding may be explained by the use of a single lymphocyte count,
obtained within 24 hours of AIS symptom onset. It may be possible that lymphocyte
suppression measured via lymphocyte count may not be detectable until a later time
point.[4] As ARG1 inhibits proliferation, there may not be an immediate change in cell
count; rather a prolonged suppression of lymphocyte proliferation would result in a
reduced count over time.
Given earlier findings by our laboratory, which demonstrate that an elevated NLR
is associated with a poor outcome within 90 days of AIS, we hypothesized that the NLR
may have a relationship with AIS severity within 24 hours of symptom onset [8]. To
address this hypothesis, we examined the relationship between NLR and AIS severity,
measured by both NIHSS and infarct volume. While the NLR was higher in severe stroke
(NIHSS>10) compared to mild (NIHSS<6), there was no statistically significant
relationship between the NLR and NIHSS. In contrast, there was a statistically significant
relationship between the NLR and infarct volume. These discrepant findings between two
measures of AIS severity are not contradicting. The NIHSS provides a standardized
assessment of neurologic deficit based on changes in cognitive and motor function, and
in this study and previous, we have shown that NIHSS and infarct volume are not always
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correlated.[17] This is especially true in AIS patients with posterior circulation strokes,
where very small infarcts can result in large neurological deficits and are reflected by
higher NIHSS scores. The strong relationship between the NLR and infarct volume
indicates that the magnitude of the immune response, as well as the factors that control
that response, are a reflection of the amount of brain tissue compromised, rather than
stroke-related symptom manifestation. In this study, the infarct volume was calculated
based on imaging obtained near the time of blood sampling. Future studies will address
how changes in both the NLR, as well as the factors that mediate the NLR, including
ARG1, contribute to the evolution of brain infarct over time after AIS.
We validated the use of a gene profile comprised of five genes, ARG1, LY96,
MMP9, s100a12, and CCR7 to diagnose AIS. This validation was necessary given that
previous validation studies utilized the reference gene β-actin, however, β-actin has been
recently shown to be an unreliable reference gene, due to variable expression levels in
AIS.[13] We utilized a combination of two genes: B2M and PPIB that have been confirmed
to be stably expressed in AIS. Compared to our previous study that had identified this
panel of five genes associated with AIS, the relative expression of only one gene, LY96,
was not increased in AIS patients in this separate cohort. The relative expression of the
four remaining genes ARG1, MMP9, s100a12, and CCR7 was comparable to previous
studies.
In addition to validating the use of this gene profile in the diagnosis of AIS, we
utilized PCA to examine the relationship between this panel of genes, AIS severity, and,
the NLR. We hypothesized that the pattern of expression amongst these genes would
have better predictive value than studying single biomarkers alone. PCA represents an
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underutilized technique for studying the complex interactions giving rise to post-stroke
immunosuppression. PC1 featured large positive loadings for ARG1 and MMP9 and a
large negative loading score for CCR7, indicating an inverse relationship between ARG1
and MMP9 expression and CCR7 expression. Further, PC1 is significantly correlated with
AIS severity and NLR, and the relationships between PC1, AIS severity, and NLR, are
stronger than the relationships between ARG1, AIS severity, and NLR. These findings
imply that recognizing patterns of biomarkers provides more clinical information than
single biomarkers alone. While PCA is merely statistical, a potential physiological
mechanism may be proposed based on these results. We postulate that the combination
of increased ARG1 expression and decreased CCR7 expression results in an increased
NLR. Because CCR7 expression mediates lymphocyte migration to secondary lymphoid
organs and lymphocyte activation, reduced CCR7 expression may represent a
mechanism of T lymphocyte suppression, mechanistically similar to the downregulation
of CD3ζ chain.[18] Future studies, including human ex-vivo and animal models of AIS,
will be necessary to examine the functional relationship between ARG1 and CCR7.
There are several limitations of this study that need to be addressed. The first
limitation is the relatively modest sample size compared to other genomic biomarker
studies. While the sample population in this study is limited, this sample size provides the
required statistical power to address the primary aims of this study. The second limitation
is the statistically significant age difference between the AIS and control groups, and the
large age range within the AIS group. To consider the understanding that immune system
function diverges with advancing age[19], we used linear regression analysis to
statistically control for age, and demonstrated that the relationships between ARG1, AIS
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severity, and NLR remain significant when accounting for age. This suggests that while
the contribution of age to these relationships exists, there are other variables that are
more significant contributors to these relationships. In addition to the large age range in
the stroke subgroup, we did not acquire TOAST classification to determine AIS etiology.
This is the first report of a relationship between ARG1, infarct volume, and NLR in
a human AIS model. This is also the first study to utilize PCA to model post-stroke
immunosuppression. PCA is an underutilized technique that has clinical utility in the study
of complex diseases, including AIS, and using PCA analysis we discovered novel
relationships between multiple biomarkers that may play a physiological role in poststroke immune suppression. The findings presented in this study have several
implications for future clinical practice. ARG1 inhibition recently entered clinical trials for
use in ischemia-reperfusion injury in patients with coronary artery disease.[20] Given the
similar pathophysiological consequences in myocardial ischemia-reperfusion injury and
AIS, it is plausible that ARG1 inhibition may represent a promising potential immune
modulating

treatment

following

AIS.

Furthermore,

because

post-stroke

immunosuppression persists for a period time in AIS recovery, ARG1 inhibition may have
a beneficial effect on AIS severity and outcome even administered at a later time point
than recanalization agents, such as rTPA.

Conclusion
Our study suggests a novel relationship exists between ARG1, NLR and stroke severity
which may help guide future mechanistic studies of post-stroke immune suppression. The
NLR is an under-utilized clinically available biomarker to monitor the post-stroke immune
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response. Future studies will need to address the functional relationships between ARG1
and NLR post-stroke to test novel immune modulating therapeutic strategies for stroke
patients.
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Table 2: Loadings from the principal component analysis with varimax rotation
using the five genes of interest: ARG1, LY96, MMP9, s100a12, and CCR7.

arg1

PC 1
0.890

PC 2
0.229

PC 3
-0.153

ly96

0.307

0.875

-0.003

mmp9
s100a12

0.852
0.001

0.016
-0.064

0.102
0.991

ccr7

-0.570

0.630

-0.218

Explained Variance (%)

38.7

24.4

21.3

Cumulative Variance Explained (%)

38.7

63.1

84.4
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Figure 1: The Relationship between ARG1 mRNA Expression, NIHSS, and NLR.
(A) ARG1 Expression is positively correlated with NIHSS (r=0.607, p<0.001).
(B) ARG1 Expression is positively correlated with NLR (r=0.582, p=0.002).
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Figure 2: The Relationship between Serum ARG1 Protein Activity, NIHSS, and NLR.
(A) Serum ARG1 Protein Activity is positively correlated with NIHSS (r=0.31, p=0.15).
(B) Serum ARG1 Protein Activity is positively correlated with NLR (r=0.52, p=0.01).
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Figure 3: Relative Expression of ARG1, LY96, MMP9, s100a12, and CCR7 in AIS.
ARG1, MMP9, and s100a12 expression are significantly increased in whole blood of AIS
patients compared to control. CCR7 expression is significantly decreased in whole blood
of AIS patients compared to control. * denotes significant increases in gene expression
in AIS (p<0.05), # denotes significant decreases in gene expression in AIS (p< 0.05).
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Background: Acute ischemic stroke (AIS) induces activation of both the innate and
adaptive arms of the immune system. While this immune response is critical to resolution
of ischemic damage in the brain, these alterations in immune function can affect systemic
immune function outside of the brain. This altered peripheral immune response has been
termed post-stroke immunosuppression and contributes to increased stroke severity,
increased rate of infection, and overall poorer recovery following stroke. Our laboratory
has shown that the baseline neutrophil-lymphocyte ratio (NLR) is a simple, inexpensive
indicator of post-stroke immunosuppression that may be used to predict outcome
following AIS. The aim of this study was to expand upon these findings and determine if
measuring the NLR after thrombolysis or at several time points, rather than at baseline
alone, may provide greater insight into stroke severity and outcome. We hypothesize that
an increase in NLR following thrombolysis is associated with increased severity and poor
outcome, regardless of the baseline NLR value prior to treatment.
Methods: AIS patients (n=18) of varying severity, as measured by NIHSS, were recruited
for this study. NLR was calculated at baseline shortly after admission, prior to intervention.
NLR was measured at a second time point following thrombolysis, approximately 24
hours following the baseline NLR. The changes in NLR (∆NLR) over 24 hours were
compared between mild, moderate, and severe AIS groups.
Results: There were no significant differences in ∆NLR over 24 hours between AIS
severity groups; however, there were observable trends in the data. The mean ∆NLR in
the mild AIS group was -0.05, compared to +2.2 and +2.8 in the moderate and severe
AIS groups, respectively.
Conclusions: This preliminary analysis provides support for the hypothesis that
measuring the NLR at a time point following thrombolysis or ∆NLR from baseline may
provide more insight into AIS patient recovery. This analysis also reaffirmed our previous
finding that baseline NLR may be used to stratify AIS patients by severity upon admission.

Introduction
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Acute ischemic stroke (AIS) induces activation of both the innate and adaptive arms of
the immune system [1,2]. Neutrophils are the first cells to migrate from the secondary
lymphoid organs and circulation to the brain following AIS [1,2]. Following a period of
inflammation as a result of neutrophil infiltration, the cells of the adaptive immune
response, specifically T lymphocytes, are activated and migrate into the brain to elicit an
antigen-specific immune response to the ischemic brain region [2,3]. While this immune
response is critical to resolution of ischemic damage in the brain, these alterations in
immune function can affect systemic immune function outside of the brain. This altered
peripheral immune response has been termed post-stroke immunosuppression, and
while the exact mechanisms that contribute to post-stroke immunosuppression are
unclear, this period of altered immune function is characterized by increased antiinflammatory cytokines, lymphopenia, and splenic atrophy [2,3]. Clinically, post-stroke
immunosuppression contributes to increased stroke severity, increased rate of infection,
and overall poorer recovery following stroke [2,3]. Our laboratory has shown that the
neutrophil-lymphocyte ratio (NLR) is a simple, inexpensive indicator of post-stroke
immunosuppression that may be used to predict outcome following AIS [4-7]. To date, all
of the studies evaluating the role of the NLR as a prognostic factor in AIS have examined
the NLR at a single time point within 24 hours of stroke symptom onset. While baseline
NLR is correlated with baseline stroke severity and also associated with poor outcome
and increased mortality within 90 days of AIS, we hypothesize that measuring the NLR at
an acute time point following thrombolysis, may provide more insight into stroke severity
and future outcome than baseline NLR. Specifically, we hypothesize that an increase in
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NLR following thrombolysis is associated with increased severity and poor outcome,
regardless of the baseline NLR value prior to treatment.

Methods
Subject Recruitment
Informed consent was obtained from all individual participants included in this study. AIS
patients and stroke-free control subjects were recruited from Ruby Memorial Hospital
(Morgantown, WV). Male and female AIS patients were eligible for recruitment if the
following inclusion criteria were met: (1) age ≥ 18 years, (2) confirmation of acute stroke
by neuroimaging (CT or MRI), and (3) had blood drawn within 24 hours of symptom
onset/”last-known normal”, prior to thrombolysis or interventional treatment. Patient data
from the medical record were reviewed and recorded, including (1) National Institutes of
Health Stroke Scale (NIHSS), (2) clinical laboratory analyses, including white blood cell
differential, and (3) brain imaging (CT/ MRI). Outcome was assessed by Modified Rankin
Scale (MRS) obtained approximately 30 days post-AIS. MRS <2 were considered as
favorable outcomes, whereas MRS ≥ 2 were considered poor outcomes.
Neutrophil-Lymphocyte Ratio
Absolute neutrophil and lymphocyte counts were derived from white blood cell
differentials, and the NLR was calculated as the absolute neutrophil count divided by
absolute lymphocyte count. White blood cell differentials were performed upon admission,
prior to thrombolysis or intervention, and repeated approximately 24 hours later. ∆NLR
was calculating by subtracting the NLR baseline from NLR 24 hr.
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Statistical Analysis
A one-way analysis of variance (one-way ANOVA) tests was used to compare the mean
NLR and ∆NLR between the mild, moderate, and severe AIS severity groups. MannWhitney U Tests were used to compare ∆NLR between AIS patient groups, straitfied by
MRS. The relationship between baseline NLR and baseline NIHSS was tested using
Spearman’s rank-order correlation.
Results
Clinical Characteristics
A total of 18 AIS patients were included in this study (8 mild, 5 moderate, and 5 severe).
There were no significant differences between groups for demographic and comorbities,
including age, sex, prior stroke, hypertension, diabetes, and dyslipidemia (Table 1). The
mean NIHSS score was significantly different between AIS severity groups (mean mild
NIHSS = 2.3 ± 0.89; mean moderate NIHSS = 8.3 ± 1.26; mean severe NIHSS = 22 ±
6.39). Ten patients (55%) received tPA (6 mild, 2 moderate, 2 severe); however, baseline
NIHSS and NLR were determined prior to tPA administration.
Baseline NLR and Stroke Severity
There is a weak unadjusted relationship between baseline NLR and baseline NIHSS
(r=0.336, p=0.17) (Figure 1). The mean baseline NLR differs between mild, moderate,
and severe AIS severity groups; however, the observed differences are not statistically
significant (mild NLR= 2.9, moderate NLR =1.7, severe NLR=3.8) (Figure 2).
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Change in NLR Over 24 hours (∆NLR) and Stroke Severity
There were no significant differences in ∆NLR over 24 hours between AIS severity
groups; however, there were observable trends in the data (Figures 3, 4). The mean
∆NLR in the mild AIS group was -0.05, compared to +2.2 and +2.8 in the moderate and
severe AIS groups, respectively. There was no difference in ∆NLR in patients who
received tPA compared to those who did not receive tPA (mean ∆NLR received tPA = 0.22, ∆NLR no tPA = +1.1).
Relationship Between baseline NLR, ∆NLR, and Outcome
There were no statistically significant differences in baseline NLR between AIS patients
with a favorable outcome (MRS <2) and poor outcome (MRS ≥2). Further, there were no
statistically significant differences in ∆NLR between AIS patients with a favorable
outcome (MRS <2) and poor outcome (MRS ≥2); however, there were greater increases
in ∆NLR in the poor outcome group compared to several decreases in ∆NLR observed in
the favorable outcome group (Figure 5).
Discussion
This preliminary analysis is the first to describe the change in NLR following thrombolysis
in AIS patients. The aim of this study was to determine if ∆NLR was more correlated with
stroke severity, as measured by NIHSS, and AIS outcome, as measured by MRS, than
baseline NLR alone. While the findings of this study lacked statistical significance, there
is evocative evidence to suggest that not only can the baseline NLR be used to stratify
AIS patients according to severity, but that measuring the change in NLR following
thrombolysis may also be indicative of acute severity, and may be a stronger indicator of
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outcome compared to baseline NLR. While this preliminary analysis may support the use
of ∆NLR as a marker of AIS outcome, there are several limitations of this study that need
to be addressed. The most concerning limitation of this study is the extremely small
sample size (n=18). Sample size becomes even more concerning when divinding study
participants into groups based on NIHSS. Having a small sample size requires practicing
caution when interpreting the the results of this study; however, the results of this study
support the investigation of this hypothesis in a larger cohort of AIS patients. Future
studies should also assess the NLR at later time points during recovery, such as 7 days,
30 days, etc. to provide even more insight into immunosuppression during recovery, as
the NLR measurements obtained during this study were taken very shortly following AIS.
In summary, while the results of this study should be interpreted cautiously, there is
preliminary evidence to suggest that the NLR following thrombolysis in AIS patients may
be a more relevant marker of AIS outcome than NLR prior to thrombolysis, and the
research questions addressed in this study warrant invesitgation in a larger patient cohort.
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Figure 1: The Relationship Between Baseline NIHSS and Baseline NLR. There is a
weak unadjusted relationship between baseline NLR and baseline NIHSS (r= 0.336,
p=0.17).
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Figure 2: Differences in Baseline NLR among AIS Severity Subgroups. The mean
baseline NLR differs between mild, moderate, and severe AIS severity groups; however,
the observed differences are not significant (mild NLR =2.9 (green), moderate NLR =1.7
(blue), severe NLR =3.8 (red)).
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Figure 3: Differences in Baseline and 24 Hour NLR among AIS Severity Subgroups.
The mean ∆NLR in the mild AIS group (green) was -0.05, compared to +2.2 and +2.8 in
the moderate (blue) and severe (red) AIS groups, respectively.
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Figure 4: Change in NLR Over 24 hours (∆NLR) in Individual Patients in AIS Severity
Subgroups. The mean ∆NLR in the mild AIS group was -0.05, compared to +2.2 and
+2.8 in the moderate and severe AIS groups, respectively. Mild AIS patients appear to
have a decrease in NLR over 24 hours, whereas severe AIS patients show an increased
in NLR over 24 hours.
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Figure 5: Relationship Between ∆NLR and AIS Outcome. There were greater
increases in ∆NLR in the poor outcome group compared to the favorable outcome group
(Mean ∆NLR favorable outcome = +0.47; mean ∆NLR poor outcome = +1.27).
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Background: Increased ARG1 expression within 24 hours of AIS symptom onset is
positively correlated with increased stroke severity, as measured by the NIH stroke
severity score (NIHSS). ARG1 expression has been shown to be associated and
functional mediator of immune system dysregulation following AIS that may represent a
functional mechanism that ARG1 may contribute to increased AIS severity; however, the
role of ARG1 in mediating AIS severity may not be limited to immune system regulation.
ARG1 can also mediate acute changes in vascular function through NO-dependent
changes in arterial muscle tone. Carotid-femoral pulse wave velocity (cfPWV) is an
assessment used to measure large-vessel arterial stiffness and is influenced by arterial
smooth muscle tone. The aims of this study were to: (1) Characterize the changes in
ARG1 expression that occur in response to AIS, (2) Characterize the changes in cfPWV
that occur in response to AIS, and (3) To determine if ARG1 expression may be a
functional mediator of vascular function following AIS. We hypothesize that increases in
both ARG1 expression and cfPWV will be associated with increased baseline stroke
severity and poor outcomes. We also hypothesize that ARG1 expression is correlated
with cfPWV at both baseline and during AIS recovery.
Methods: Whole blood samples were drawn from AIS patients on three separate time
points: baseline, 30 days, and 90 days after AIS. cIMT and cfPWV were also measured
on three separate time points: baseline, 30 days, and 90 days following stroke.
Results: There is a strong unadjusted relationship between baseline ARG1 expression
and baseline NIHSS. In mild AIS, cfPWV remains stable from baseline to 30 days poststroke. In contrast, cfPWV increased from baseline to 30 days post-stroke in severe AIS.
Lastly, there appears to be a relationship between ∆ARG1 and ∆cfPWV from baseline to
30 days post-stroke
Conclusions: Overall, we have described a novel relationship between ARG1
expression and cfPWV and AIS severity and recovery. ARG1 inhibition following AIS may
represent a novel therapeutic strategy that may improve both immune and vascular
function following AIS.
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Introduction
We have recently identified Arginase 1 (ARG1) as a marker of acute ischemic stroke (AIS)
severity and outcome [1]. Specifically, increased ARG1 expression within 24 hours of AIS
symptom onset is positively correlated with increased stroke severity, as measured by
the NIH stroke severity score (NIHSS). Further, ARG1 expression has been shown to be
associated and functional mediator of immune system dysregulation following AIS that
may represent a functional mechanism that ARG1 may contribute to increased AIS
severity; however, the role of ARG1 in mediating AIS severity may not be limited to
immune system regulation. In addition to its role in regulating the immune response,
ARG1 has been shown to affect vascular function by limiting the metabolism of L-arginine
by nitric oxide synthases to nitric oxide (NO). This leads to decreased NO, resulting in
changes in arterial structure, such as smooth muscle cell hypertrophy and increased
collagen synthesis [2]. In addition to changes in arterial structure, ARG1 can also mediate
acute changes in vascular function through NO-dependent changes in vasomechanics.
Carotid-femoral pulse wave velocity (cfPWV) is an assessment used to measure largevessel arterial stiffness, and cfPWV is influenced by mean arterial pressure and arterial
smooth muscle tone [3]. To this end, because of the role of NO in mediating vascular
tone, acute changes in NO concentration can result in changes in cfPWV. Specifically,
pharmacological NO inhibition has been shown to acutely increase cfPWV in human
subjects [4]; therefore, given the role of ARG1 as an endogenous NO inhibitor, it is likely
that increased ARG1 can also increase arterial stiffness (cfPWV) through a similar
mechanism; however, there have been no studies to date examining the relationship
between ARG1 expression and cfPWV. Further, while increased cfPWV has been
identified as a risk factor for AIS [5], the changes in cfPWV as a result of AIS and how
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these changes impact AIS recovery are unclear. The aims of this study were to: (1)
Characterize the changes in ARG1 expression that occur in response to AIS, (2)
Characterize the changes in cfPWV that occur in response to AIS, and (3) To determine
if ARG1 expression may be a functional mediator of vascular function, specifically cIMT
and cfPWV, following AIS. We hypothesize that increases in both ARG1 expression and
cfPWV will be associated with increased baseline stroke severity and poor outcomes. We
also hypothesize that ARG1 expression is correlated with cfPWV at both baseline and
during AIS recovery.

Methods
Subject Recruitment
Informed consent was obtained from all individual participants included in the study. AIS
patients and stroke-free control subjects were recruited from Ruby Memorial Hospital
(Morgantown, WV). Male and female AIS patients were eligible for recruitment if the
following inclusion criteria were met: (1) age ≥ 18 years, (2) confirmation of acute stroke
by neuroimaging (CT or MRI), and (3) had blood drawn within 24 hours of symptom
onset/”last-known normal”, prior to thrombolysis or interventional treatment. Patient data
from the medical record were reviewed and recorded, including (1) National Institutes of
Health Stroke Scale (NIHSS), (2) clinical laboratory analyses, including white blood cell
differential, and (3) brain imaging (CT/ MRI). Stroke-free control subjects were eligible for
recruitment if the following inclusion criteria were met: (1) age ≥ 18 years, and (2) no
history of AIS, transient ischemic attack, brain injury, or other overt central nervous
system disease, and (3) recent hospitalization. Medical histories were obtained directly
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from stroke-free control subjects; however, complete access to medical records of control
subjects was not available.

Research Protocol Approval and Informed Consent
This study received approval for human subject research from the institutional review
boards of West Virginia University and Ruby Memorial Hospital (Morgantown, WV).
Written informed consent was obtained from all subjects or their authorized
representatives prior to performing study procedures.

Study Design
Whole blood samples were drawn from AIS patients on three separate time points:
baseline (0-12 hours from symptom onset), 30 days, and 90 days after AIS. cIMT and
cfPWV were also measured on three separate time points: baseline (24-48 hours of
symptom onset, 30 days, and 90 days following stroke. For the 30 and 90 day time points,
blood sample collection occurred immediately prior to CV assessments.

Blood Sample Collection
Peripheral venous whole blood was drawn from stroke subjects no later than 24 hours of
stroke symptom onset. Blood was collected into PAXgene

Blood RNA tubes (Becton-

Dickinson). Immediately after blood collection, tubes were inverted 8-10 times and stored
at -80°C until analysis.
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Gene Expression Analysis
PAXgene

Blood RNA tubes were thawed overnight (16-20 hrs) at room temperature

prior to RNA extraction. The PAXgene Blood RNA kit (Pre-Analytix) was used to
purify/extract intracellular RNA, per manufacturer’s instructions. RNA concentration and
quality was determined by absorbance using a Take3 Trio Microplate (BioTek

) read on

a Syntek Hybrid Plate Reader, and analyzed using Gen5 (BioTek) software. A260/A280
values between 1.8 and 2.2 were considered acceptable RNA quality.
RNA was converted to cDNA using the High-Capacity Reverse Transcription Kit (Applied
Biosystems). cDNA (10 ng) was used for quantitative real-time PCR amplification using
SYBR Green chemistry using the Rotor-Gene Q real-time PCR cycler (Qiagen). The
following Quantitect primers were used: ARG1 (NM_000045,NM_001244438)and PPIB
(NM_000942) (Qiagen). PPIB served as a stable, endogenous reference gene to
normalize ARG1 expression.

Arterial Function
Pulse wave analysis was performed non-invasively on the right radial artery
(SphygmoCor system, AtCor Medical, Sydney, NSW, Australia). From the radial artery
pressure wave, the SphygmoCor system calculates a central pressure waveform that
accurately replicates the ascending aortic pressure wave obtained from invasive
measures. From the central wave, central blood pressure was also determined. Cf-PWV
was obtained using the SpygmoCor XCEL PWV device (SphygmoCor system, AtCor
Medical, Sydney, NSW, Australia). A cuff was placed around the femoral artery of the
subject to capture the femoral waveform/pulse, and a tonometer pressure sensor was

86

used to capture the carotid waveform/pulse. The pulse transit time is the time that the
pulse takes to travel from the carotid to the femoral artery. The distance between the
carotid and femoral arteries was measured for each subject, and the cfPWV automatically
determined by dividing the distance by the pulse transit time.

Arterial Geometry
In the supine position, B-mode ultrasound (GE Vivid I; GE healthcare, Chalfont St Giles,
UK) images were obtained of the right common carotid artery, 1-2 cm proximal to the
carotid bifurcation to measure cIMT.

Statistical Analysis
The relationships between ARG1 expression, NIHSS, cIMT, and cfPWV were tested
using Spearman’s rank-order correlations. Linear regression analysis was used to identify
statistically significant relationships when controlling for confounding variables,
specifically age, sex, hypertension, diabetes, dyslipidemia, and smoking.

Results
Clinical Characteristics
A total of 12 subjects participated in this study, and subjects’ demographic information is
summarized in Table 1. In addition, the mean baseline cIMT for the subject cohort was
0.59 ± 0.08 mm (mean ± SD), and the mean baseline cfPWV was 9 ± 1 m/s (mean ± SD).

87

Relationship between ARG1 and Stroke Severity
There is a strong unadjusted relationship between baseline ARG1 expression and
baseline NIHSS (r=0.660, p=0.038) (Figure 1). After linear regression analysis controlling
for age, sex, HTN, DM, dyslipidemia, and prior stroke, the relationship between baseline
ARG1 expression and baseline NIHSS remained significant (p=0.032). Further, there is
a strong unadjusted relationship between 30 day ARG1 expression and baseline NIHSS
(r=0.766, p=0.01) (not shown). After linear regression analysis controlling for age, sex,
HTN, DM, dyslipidemia, prior stroke, and tPA treatment, the relationship between 30 day
ARG1 expression and baseline NIHSS was no longer significant (p=0.401).

Change in ARG1 Expression 30 Days Post-Stroke
While our limited sample size does not allow for meaningful statistical analysis, we
observed several trends in changes in ARG1 expression 30 days post-stroke (Figure 2).
As expected, we observed that in a single control subject ARG1 expression remained
stable from baseline to 30 days. Upon examination of n=2 mild AIS patients, we observe
a decrease in ARG1 expression from baseline to 30 days. In contrast, we observed that
in a single severe AIS patient, ARG1 expression increased from baseline to 30 days poststroke. In the moderate AIS group (n=2), there were both increases and decreases in
ARG1 expression from baseline to 30 days.

Change in cfPWV 90 Days Post-Stroke

88

While our limited sample size does not allow for meaningful statistical analysis, we
observed several trends in changes in cfPWV from baseline to 90 days post-stroke
(Figure 3). As expected, we observed that in a single control subject cfPWV remained
stable from baseline to 30 days. Upon examination of n=3 mild AIS patients, we observe
a decrease in cfPWV from baseline to 30 days (no 90 day data available). Further, in the
mild group, cfPWV remains stable from 30 to 90 days post-stroke. In contrast, we
observed that in a single severe AIS patient, cfPWV increased from baseline to 30 days
post-stroke (no 90 day data available).

Relationship between ARG1 and cfPWV
While our limited sample size does not allow for meaningful statistical analysis, there
appears to be a relationship between ∆ARG1 and ∆cfPWV from baseline to 30 days poststroke (Figure 4). In a single control subject, we observe that neither cfPWV nor ARG1
expression changes from baseline to 30 day follow-up visit. In a single mild AIS patient,
we observe that a large decrease in cfPWV is associated with a decrease in ARG1
expression. In contrast, in a single severe AIS patient, we observe that a large increase
in cfPWV is associated with a increase in ARG1 expression.

Relationship between ARG1 and cIMT
There was not a significant relationship between ARG1 and cIMT neither at baseline
(r=0.098, p=0.817) nor at 30 days post-stroke (r=0.083, p=0.167) (not shown). Further,
there were no notable decreases in cIMT in any of the subjects across the 10-week
lifestyle intervention, and subsequently, no correlation between ∆ARG1 and ∆cIMT.
Discussion
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This is the first study aimed to characterize the changes in ARG1 expression and vascular
function that occur in response to AIS. While this study is preliminary and evocative in
nature, we have both confirmed relationships that had been described in previous studies
and also provide novel evidence to support patterns of ARG1 expression and changes in
cfPWV that may be observed following AIS. First, we confirmed that baseline ARG1 is a
marker of AIS severity, as measured by NIHSS. Specifically, increased baseline ARG1 is
correlated with increased NIHSS. We have expanded this finding to describe how
changes in ARG1 expression that occur following AIS relate to AIS recovery. We have
shown that there are AIS severity-dependent changes in ARG1 expression that occur
during recovery. Specifically, we have shown that not only is baseline ARG1 expression
lower in mild AIS patients compared to severe, but also that ARG1 expression tends to
decrease over a 30-day recovery period. In contrast, in severe AIS, ARG1 expression
tends to decrease over a 30-day recovery period. This marked difference in ΔARG1
between mild and severe groups may represent a functional mechanism that may account
for poor recovery seen in severe AIS patients. Further, this elevated ARG1 expression,
at both baseline and 30 days into recovery in severe AIS patients, may contribute to poor
recovery via mechanisms that are independent of the degree of brain damage suffered
at baseline. We have previously shown that the neutrophil-lymphocyte ratio (NLR) is a
marker of immune dysfunction following AIS that is associated with increased AIS severity
and poor recovery. Specifically, an increased baseline NLR is associated with stroke
severity and is predictive of AIS outcome, as measured by the Modified Rankin Scale
[1,6]. Further, we have examined the change in NLR from baseline to 30 days post-AIS
and reported that severe AIS patients have an overall increase in NLR from baseline to
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30 days, whereas mild AIS patients have a decrease or no change in NLR over the 30day recovery period (Petrone, unpublished). We have also shown that baseline ARG1
expression is positively correlated with baseline NLR [1]. Combining the results of these
previous studies and the current study, we may speculate that ARG1 may be the mediator
of NLR at both baseline and during recovery.
While we have established ample evidence to suggest that ARG1 contributes to
increased AIS severity and poor outcome following AIS by altering immune function, we
hypothesized that the role of ARG1 in AIS was not limited to mediating the immune
response, given its traditional role in mediating vascular function. In support of our
hypothesis, we have established a relationship between ARG1 expression and cfPWV
following AIS. Further, independent of ARG1 expression, we have characterized the
changes in cfPWV that occur following AIS. In summary, severe AIS patients have an
overall increase in cfPWV from baseline to 30 days, whereas mild AIS patients have a
decrease or no change in cfPWV over the 30-day recovery period. While it is generally
agreed, that increased cfPWV is indicative of poor CV health, future studies are needed
to address the molecular mechanisms resulting in an increase in cfPWV following stroke,
because it may be possible that increased cfPWV in response to AIS may be a
physiological response to decrease AIS severity.
Overall, we have described a relationship between ARG1 expression and cfPWV
during AIS recovery. ARG1 inhibition following AIS may represent a novel therapeutic
strategy, administered both acutely and chronically following AIS, and the beneficial
mechanism of action of ARG1 inhibition may target not only one, but several
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pathophysiological mechanisms following AIS, including both immune dysregulation and
vascular dysfunction.
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Figure 1: The Relationship between ARG1 Expression and AIS Severity. There is a
strong unadjusted relationship between baseline ARG1 expression and baseline NIHSS
(r=0.660, p=0.038).

Figure 2: Changes in ARG1 Expression in AIS Recovery. In a single control subject
ARG1 expression remained stable from baseline to 30 days (orange). In mild AIS
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patients, there is a decrease in ARG1 expression from baseline to 30 days (green).
ARG1 expression increased from baseline to 30 days post-stroke in severe AIS (red). In
the moderate AIS group (n=2), there were both increases and decreases in ARG1
expression from baseline to 30 days (blue).

Figure 3: Changes in cfPWV in AIS Recovery. In a single control subject, cfPWV
remained stable from baseline to 30 days (orange). In the mild AIS group, there is a
decrease in cfPWV from baseline to 30 days (green). Further, in the mild group, cfPWV
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remains stable from 30 to 90 days post-stroke (green). In a single severe AIS patient,
cfPWV increased from baseline to 30 days post-stroke (red).

Figure 4: Relationship between ARG1 Expression and cfPWV in AIS Recovery. In
a single control subject, neither cfPWV nor ARG1 expression changes from baseline to
30-day follow-up (orange). In a single mild AIS patient, there is a large decrease in
cfPWV is associated with a decrease in ARG1 expression (green). In a single severe
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AIS patient, there is large increase in cfPWV is associated with an increase in ARG1
expression (red).
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Background: Arginase 1 (ARG1) had been established as a mediator of endothelial
function. Specifically, ARG1 limits the metabolism of L-arginine by both iNOS and eNOS
to NO, resulting in changes in arterial structure, such as smooth muscle cell hypertrophy
and increased collagen synthesis. We have previously characterized the changes in
carotid-intima medial thickness (cIMT) and carotid-femoral pulse wave velocity (cfPWV)
that occur post-stroke; however, because stroke recovery is generally associated with
treatment and improvement of CV risk factors, such as hypertension and diabetes, it is
difficult to distinguish the changes in cIMT and cfPWV that are a direct response to stroke
from those that result from overall CV health improvements. The goal of this study was to
characterize the changes in ARG1 expression, as well as cIMT and cfPWV, following a
10-week lifestyle modification, and we hypothesize that decreases in CV risk factors will
correlate with decreases in ARG1 expression.
Methods: CVD subjects were assessed at beginning of the study and following a 10week lifestyle modification program designed to reduce CV risk factors. Body
composition, functional exercise capacity, and vascular assessments (cIMT and cfPWV)
were performed at each time point. Blood samples were also collected to quantify ARG1
expression.
Results: There was an unadjusted positive correlation between baseline ARG1
expression and both cIMT (r=0.844, p=0.001) and cfPWV (r=0.743, p=0.006). There were
no substantial changes in cIMT across the 10-week intervention; however, several
subjects in the cohort had substantial changes in cfPWV (∆cfPWV) and ARG1 (∆ARG1).
Further, there was an unadjusted positive correlation between ∆cfPWV and ∆ARG1
(r=0.703, p=0.016).
Conclusions: This is the first report of a relationship between ARG1, cfPWV, and cIMT
in subjects with CV risk factors. While this preliminary analysis requires validation to
confirm the relationships described herein, it appears as that ARG1 may be a mediator
of cfPWV. With the ultimate goal of developing an ARG1 inhibitor for therapeutic use, this
study provides support for the hypothesis that ARG1 inhibition may be used as a proactive
therapeutic to improve CV health.
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Introduction
We have recently identified Arginase 1 (ARG1) as a marker of immune dysfunction
following ischemic stroke [1). Further, ARG1 may mediate changes in immune function,
as well as other physiological processes, that contribute to increased risk of stroke and
poor recovery. Prior to the association between ARG1 and immune function, ARG1 had
been established as a mediator of endothelial function [2]. Specifically, ARG1 limits the
metabolism of L-arginine by both iNOS and eNOS to NO, which leads to decreased NO,
resulting in changes in arterial structure, such as smooth muscle cell hypertrophy and
increased collagen synthesis [2]. These changes in structure result in medial wall
thickening and arterial stiffness. Arterial stiffness has been identified as a risk factor for
several cardiovascular diseases, including ischemic stroke, thus strategies to reduce
arterial stiffness and prevent abhorrent vascular remodeling, may serve as a proactive
therapeutic to reduce the risk of stroke [3]. We have previously characterized the changes
in carotid-intima medial thickness (cIMT) and carotid-femoral pulse wave velocity (cfPWV)
that occur post-stroke [Petrone unpublished, chapter 3]; however, because stroke
recovery is generally associated with treatment and improvement of CV risk factors, such
as hypertension and diabetes, it is difficult to distinguish the changes in cIMT and cfPWV
that are a direct response to stroke from those that result from overall CV health
improvements. Further, we described the relationship between changes in ARG1
expression that occur along with changes in cIMT and cfPWV following stroke, but
similarly, the changes in ARG1 expression that are a direct function of stroke are difficult
to distinguish from changes in CV function. There is a large body of evidence that
suggests that current CV risk management therapeutics, such as statins, inhibit arginase
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activity, and in addition to their primary target effect, some of the efficacy of these drugs
may be the result of the off-target arginase inhibition [4]. To this end, a specific-ARG1
inhibitor may be a potential therapeutic strategy in CV disease, stroke, and likely several
other conditions; however, more information is needed to understand the functional role
of ARG1 and the patterns of expression that occur over time in response to various
conditions. The goal of this study was to characterize the changes in ARG1 expression,
as well as cIMT and cfPWV, following a 10-week lifestyle modification. This 10-week
intervention was designed to improve CV health, in a similar fashion and timeline that we
assessed in ischemic stroke patients (Petrone, unpublished Chapter 3). We hypothesize
that decreases in CV risk factors, such as cIMT, cfPWV, blood pressure, and body weight,
will correlate with decreases in ARG1 expression.

Methods
Subject Recruitment
Informed written consent was obtained from all subjects prior to study participation.
Subjects were eligible for study participation if diagnosed with CVD, as defined by the
criteria listed in Table 1.

Study Design
The rural Health/Heart Accelerating Research Transition (rHEART) was developed to
promote healthy lifestyle changes in a rural population. The key feature of this study was
to engage the subjects’ family members or friends to participate with the subject to
promote healthy lifestyle changes through accountability in the subject’s home
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environment. Each subject had the following samples/measurements taken before and
following a 10-week lifestyle intervention that included diet modification and weekly
sessions to educate subjects on CVD health, including smoking cessation, stress
management, physical activity, etc.

Body Composition and Physical Performance
Anthropometric assessments, including height and weight, were used to measure body
mass index (BMI), as a measure of obesity (BMI>30). The 6-minute walk test (6MWT)
was used to compare functional exercise capacity. The subjects were asked to walk back
and forth over a 30-meter distance, and the distance walked in 6 minutes was recorded.
The 6MWT is inexpensive and easy to administer in a variety of locations, and is also less
strenuous than a typical cardiac stress test, but still able to yield accurate information
regarding functional exercise capacity [5].

CV Assessments
All CV assessments were obtained when subjects were fasted for at least 12 hours and
after a minimum of 15 minutes quiet rest. Subjects were also asked to abstain from
alcohol, caffeine, vitamins, and any other health supplement 24 hours prior to
assessments. Further, CV assessments were obtained at the same time of the day both
prior to and following the 10-week intervention.

Arterial Function
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Pulse wave analysis was performed non-invasively on the right radial artery
(SphygmoCor system, AtCor Medical, Sydney, NSW, Australia). From the radial artery
pressure wave, the SphygmoCor system calculates a central pressure waveform that
accurately replicates the ascending aortic pressure wave obtained from invasive
measures. From the central wave, central blood pressure was also determined. Cf-PWV
was obtained using the SpygmoCor XCEL PWV device (SphygmoCor system, AtCor
Medical, Sydney, NSW, Australia). A cuff was placed around the femoral artery of the
subject to capture the femoral waveform/pulse, and a tonometer pressure sensor was
used to capture the carotid waveform/pulse. The pulse transit time is the time that the
pulse takes to travel from the carotid to the femoral artery. The distance between the
carotid and femoral arteries was measured for each subject, and the cfPWV automatically
determined by dividing the distance by the pulse transit time.

Arterial Geometry
In the supine position, B-mode ultrasound (GE Vivid I; GE healthcare, Chalfont St Giles,
UK) images were obtained of the right common carotid artery, 1-2 cm proximal to the
carotid bifurcation to measure cIMT.

Blood Sample Collection
Venous blood was drawn to perform a metabolic panel to identify total cholesterol, highdensity lipoprotein (HDL), triglycerides, hemoglobin, and glucose levels following a 12
hour fast. Further, subjects’ medical history was recorded for age, sex, smoking status,
diabetes, hypertension, and other relevant health history. In addition to the metabolic
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panel, a second blood sample was collected into PAXgene

Blood RNA tubes (Becton-

Dickinson) for gene expression analysis. Immediately after blood collection, PAXgene
tubes were inverted 8-10 times and stored at -80°C until analysis.

Gene Expression Analysis
PAXgene

Blood RNA tubes were thawed overnight (16-20 hrs) at room temperature

prior to RNA extraction. The PAXgene Blood RNA kit (Pre-Analytix) was used to
purify/extract intracellular RNA, per manufacturer’s instructions. RNA concentration and
quality was determined by absorbance using a Take3 Trio Microplate (BioTek

) read on

a Syntek Hybrid Plate Reader, and analyzed using Gen5 (BioTek) software. A260/A280
values between 1.8 and 2.2 were considered acceptable RNA quality.
RNA was converted to cDNA using the High-Capacity Reverse Transcription Kit (Applied
Biosystems). cDNA (10 ng) was used for quantitative real-time PCR amplification using
SYBR Green chemistry using the Rotor-Gene Q real-time PCR cycler (Qiagen). The
following Quantitect primers were used: ARG1 (NM_000045,NM_001244438)and PPIB
(NM_000942) (Qiagen). PPIB served as a stable, endogenous reference gene to
normalize ARG1 expression.

Statistical Analysis
The relationships between ARG1 expression, cIMT, and cfPWV were tested using
Spearman’s rank-order correlations. Linear regression analysis was used to identify
statstically significant relationships when controlling for confounding variables,
specifically age, sex, hypertension, diabetes, dyslipidemia, and smoking.
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Results
Clinical Characteristics
A total of 12 subjects participated in this study, and subjects’ demographic information is
summarized in Table 2. The subject cohort was predominantly female (92%) and the
subjects’ ages ranged from 20-76 years. The mean pre-intervention cIMT for the subject
cohort was 0.65 ± 0.17 mm (mean ± SD), and the mean pre-intervention cfPWV was 8 ±
1.7 m/s (mean ± SD).

Relationship between cIMT and cfPWV
There is a significant unadjusted relationship between cIMT and cfPWV (r=0.758,
p=0.004) (Figure 1). After linear regression analysis controlling for age, sex, HTN, DM,
dyslipidemia, and smoking, the relationship between cIMT and cfPWV is not significantly
significant (p=0.405). However, both cIMT (r=0.853, p=0.000) and cfPWV (r=0.797,
p=0.000) are strongly correlated with age, and when age is not included as an
independent variable in linear regression analysis, the relationship between cIMT and
cfPWV is statistically significant controlling for the remaining confounders (p=0.018).

Relationship between ARG1 and CV Assessments
There is an unadjusted positive correlation between ARG1 mRNA expression and both
cIMT (r=0.844, p=0.001) (Figure 2) and cfPWV (r=0.743, p=0.006) (Figure 3). After linear
regression analysis controlling for age, sex, HTN, DM, dyslipidemia, and smoking, the
relationship between ARG1 and cIMT remains weakly significant (p=0.18). However,
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upon removal of age from regression analysis, the relationship between ARG1 and cIMT
is statistically significant controlling for the remaining confounders (p=0.019). Similarly,
after linear regression analysis controlling for age, sex, HTN, DM, dyslipidemia, and
smoking, the relationship between ARG1 and cfPWV is not statistically significant
(p=0.526). However, upon removal of age from regression analysis, the relationship
between ARG1 and cfPWV is statistically significant controlling for the remaining
confounders (p=0.054).
There were no substantial changes in cIMT across the 10-week intervention;
however, several subjects in the cohort had substantial changes in cfPWV (∆cfPWV) and
ARG1 (∆ARG1). Further, there was an unadjusted positive correlation between ∆cfPWV
and ∆ARG1 (r=0.703, p=0.016) (Figure 4); however, after linear regression analysis
controlling for age, sex, HTN, DM, dyslipidemia, and smoking, the relationship between
∆ARG1 and ∆cfPWV is not statistically significant (p=0.444), nor when removing age from
the regression analysis (p=0.244).

Discussion
To our knowledge, this is one of the only studies to directly characterize the relationship
between ARG1 expression, cIMT, and cfPWV. Further, this is the only study to assess
changes in ARG1 expression following a 10-week lifestyle modification program. First,
similar to previous reports, we confirmed the strong relationship between cIMT and
cfPWV. While cIMT is typically used to assess arterial geometry, and cfPWV is used to
measure arterial stiffness, both measures are considered gold-standard techniques to
assess overall vascular function. Because cfPWV has been shown to change more
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acutely than cIMT, we expected to see very little change in cIMT over the 10-week
intervention, but we hypothesized that decreases in CV risk factors over the 10-week
intervention would correlate with decreases in cfPWV. There were no associations
between decreased body weight, cholesterol, triglycerides, increased functional exercise
capacity, and cfPWV. However, in support of our primary hypothesis, we did observe a
correlation between the 10-week ∆cfPWV and ∆ARG1 expression (r=0.703, p=0.016),
indicating that ARG1 may be a functional mediator of cfPWV.
There are several limitations of this study that need to be addressed. First, the
sample size included in this study is extremely small (n=12) and the results presented
here should be interpreted as preliminary and evocative in nature. While there were
strong, unadjusted relationships between ARG1 expression, cIMT, and cfPWV, these
relationships were not significant when adjusting for confounding regressors. Specifically,
each of the variables in question, ARG1, cfPWV, and cIMT have a strong positive
correlation with increasing age, such that the relationships may be accounted for solely
by age, rather than a representation of a functional relationship between the variables.
To address this possibility, a larger sample size will be required in future studies. Further,
a subject cohort with a limited age range may be used to reduce the impact of age in
order to determine the true functional relationships between ARG1, cIMT, and cfPWV.
The second limitation of this study is that the 10-week lifestyle modification produced very
modest improvements in overall CV function, as measured by the metrics in this study.
Despite this, we did observe a relationship between ∆cfPWV and ∆ARG1 expression,
where decreases in cfPWV were correlated with decreased ARG1 expression; however,
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a longer intervention or an intervention that leads to greater improvements in CV health
may provide better evidence for a role of ARG1 in mediating these improvements.
In summary, this is the first report of a relationship between ARG1, cfPWV, and
cIMT in subjects with CV risk factors. While this preliminary analysis requires validation
to confirm the relationships described herein, it appears as that ARG1 may be a mediator
of cfPWV. With the ultimate goal of developing an ARG1 inhibitor for therapeutic use in
ischemic stroke, this study provides support for the hypothesis that ARG1 inhibition,
administered in the months following stroke, may improve stroke outcomes, and ARG1
inhibition may be used as a proactive therapeutic to improve CV health.
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Table 1: Study Inclusion Criteria
At least one of the following criteria were met to be defined as having CVD and
to be eligible for study participation:
(1) Prior Myocardial Infarction (>2 months)
(2) Revascularization Procedure for Coronary Artery Disease (>2 months)
(3) Heart Disease
(4) Stroke (>2 months)
(5) Type II Diabetes
(6) Hypertension – BP >140/90 or taking antihypertensive medication
(7) Obesity (BMI≥30)
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Figure 1. Relationship between cIMT and cfPWV. There is a significant unadjusted
relationship between cIMT and cfPWV (r=0.758, p=0.004).
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Figure 2. Relationship between cIMT and ARG1 Expression. There is an unadjusted
positive correlation between ARG1 mRNA expression and cIMT (r=0.844, p=0.001).

112

Figure 3. Relationship between cfPWV and ARG1 Expression. There is an unadjusted
positive correlation between ARG1 mRNA expression and cfPWV (r=0.743, p=0.006).
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Figure 4. Relationship between ∆cfPWV and ∆ARG1 Expression. There is an
unadjusted positive correlation between ∆cfPWV and ∆ARG1 (r=0.703, p=0.016).
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Background: There have been several studies evaluating the changes in gene
expression in whole blood in response to AIS, and several markers have been identified
by multiple studies. Of particular interest is the gene Arginase 1 (ARG1) that has been
reported to be roughly 3-fold higher in the whole blood of AIS patients within 24 hours of
AIS compared to healthy control subjects. We have recently shown that increased whole
blood ARG1 expression is associated with increased AIS severity, immunosuppression,
and poor outcome following AIS. In human control subjects, ARG1 expression is highest
in neutrophils compared to other peripheral blood leukocytes. Despite this finding, the
role and cellular origin of ARG1 protein in AIS remains to be determined. Thus our
hypothesis was two-fold; first, ARG1 protein levels would be higher in the neutrophils of
AIS patients compared to controls. Second, that within the AIS group, neutrophil ARG1
protein levels would be higher in severe AIS compared to mild.
Methods: Peripheral venous whole blood was drawn from controls and from stroke
subjects no later than 24 hours of stroke symptom onset. Following RBC lysis, leukocytes
were pelleted and fixed. Fixed leukocytes were isolated and intracellular ARG1 was
stained and measured by Flow Cytometry. Mann-Whitney U Tests were used to compare
intracellular ARG1 between AIS and control groups and also between mild and severe
AIS groups.
Results: Intracellular ARG1 was detected in both the neutrophil and monocyte fractions
in both AIS and control patients; however, neither neutrophil nor monocyte ARG1 levels
significantly differed between AIS and control. Further, in both AIS and control, ARG1
was detected at a higher level in the neutrophil fraction compared to the monocyte
fraction. Within the AIS group, neutrophil ARG1 was significantly higher in the severe
group compared to the mild AIS group (p=0.008)
Conclusions: Overall, the results of this study suggest that ARG1 protein expression is
highest in neutrophils compared to other leukocyte populations. Neutrophil ARG1 may
also increase in response to brain damage in severe AIS. These findings suggest that
inhibition of systemic ARG1 protein may improve AIS outcome, and neutrophils may be
a therapeutic target for ARG1 inhibition.

Introduction
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The immune system plays a vital role in acute ischemic stroke (AIS) incidence,
pathophysiology, and recovery [1,2]. While an immune response is critical to resolution
of ischemic damage in the brain, these alterations in immune function can affect systemic
immune function outside of the brain. There have been a large number of studies
evaluating the changes in inflammatory markers, immune cell profiles, and other
measures of immune function in both the peripheral blood and brain following AIS. While
a complete understanding of all of the alterations in immune function in response to AIS
are remains unknown, it is generally agreed upon that there is an acute increase in proinflammatory cytokines, such as IL-6 and TNFα, in both the brain and periphery [2,3].
Despite this rapid increase in inflammation, there is also a degree of immune suppression
that

occurs

systemically,

immunosuppression

is

termed

post-stroke

immunosuppression.

Post-stroke

characterized by increased anti-inflammatory cytokines,

lymphopenia, and splenic atrophy [4]; however, the molecular mechanisms giving rise to
this clinical phenomenon are unknown. There have been several studies evaluating the
changes in gene expression in whole blood in response to AIS, and although independent
investigators performed these studies, several markers have been identified by multiple
studies. Of particular interest is the gene Arginase 1 (ARG1) that has been reported to be
roughly 3-fold higher in the whole blood of AIS patients within 24 hours of AIS compared
to healthy control subjects [5-7]. We have also recently shown that increased whole blood
ARG1 expression is associated with increased AIS severity, immunosuppression, and
poor outcome following AIS [6]. In humans, ARG1 expression is highest in neutrophils
compared to other peripheral blood leukocytes [7], and ARG1 protein released from
neutrophils suppresses T lymphocyte proliferation through downregulation of T
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lymphocyte CD3ζ chain [8]. Despite this, the role and cellular origin of ARG1 protein in
AIS remains to be determined. The aims of this study were to expand upon previous
studies to (1) Determine whether ARG1 protein, in addition to mRNA expression, is
highest within neutrophils compared to other leukocyte fractions, (2) Determine if
neutrophil ARG1 protein levels differ between AIS and control and (3) Characterize the
change in neutrophil ARG1 protein that may occur with increasing AIS severity. We
hypothesize that ARG1 protein will be highest in neutrophils compared to other leukocyte
populations in both AIS and control; however, ARG1 protein levels will be higher in the
neutrophils of AIS patients compared to controls. Further, we hypothesize that within the
AIS group, neutrophil ARG1 protein levels will be higher in severe AIS compared to mild.

Methods

Subject Recruitment
Informed consent was obtained from all individual participants included in the study. AIS
patients and stroke-free control subjects were recruited from Ruby Memorial Hospital
(Morgantown, WV). Male and female AIS patients were eligible for recruitment if the
following inclusion criteria were met: (1) age ≥ 18 years, (2) confirmation of acute stroke
by neuroimaging (CT or MRI), and (3) had blood drawn within 24 hours of symptom
onset/”last-known normal”, prior to thrombolysis or interventional treatment. Patient data
from the medical record were reviewed and recorded, including (1) National Institutes of
Health Stroke Scale (NIHSS), (2) clinical laboratory analyses, including white blood cell
differential, and (3) brain imaging (CT/ MRI). Stroke-free control subjects were eligible for
recruitment if the following inclusion criteria were met: (1) age ≥ 18 years, and (2) no
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history of AIS, transient ischemic attack, brain injury, or other overt central nervous
system disease, and (3) recent hospitalization. Medical histories were obtained directly
from stroke-free control subjects; however, complete access to medical records of control
subjects was not available.

Blood Sample Collection
Peripheral venous whole blood was drawn from controls and from stroke subjects no later
than 24 hours of stroke symptom onset. Approximately 8mL of whole blood was collected
into EDTA vacutainers, gently inverted 8-10 times and remained at room temperature
(RT) for 20 minutes prior to processing.

Fixation of Leukocytes from Whole Blood
Whole blood samples were processed within one hour of collection. Whole blood was
mixed with ACK lysis buffer (Life Technologies) to lyse red blood cells from each sample
per manufacturer’s instructions. Following RBC lysis, leukocytes were pelleted and fixed
in preparation for surface and intracellular staining by Flow Cytometry. Leukocytes were
resuspended in 2mL PBS, 2mL neutral-buffered formalin (NBF), vortexed immediately
following addition of NBF, and incubated for 10 minutes at RT. Following incubation,
leukocytes were pelleted and resuspended in cell culture preservation media, aliquoted,
and placed in a cryopreservation container for ~6 hours before moving samples to -80°C
until analysis for fixed-rate freezing.

Determination of ARG1 by Flow Cytometry
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Fixed leukocytes were isolated using surface markers and intracellular ARG1 was stained
and measured by Flow Cytometry. ARG1 was measured in T lymphocytes, monocytes,
and neutrophils. The surface marker CD3 was used to stain T lymphocytes, CD14 for
monocytes, and CD15 for neutrophils. Each leukocyte subpopulation was also stained for
intracellular ARG1-APC. APC fluorescence was determined by Flow Cytometry and used
to quantify ARG1 in each leukocyte population.

Statistical Analysis
Mann-Whitney U Tests were used to compare intracellular ARG1 between AIS and
control groups and also between mild and severe AIS groups. For group comparisons,
mild and moderate AIS were combined to compare against severe AIS. Linear regression
analysis was used to identify statstically significant relationships between groups when
controlling for confounding regressors, specifically age, sex, hypertension, diabetes, prior
stroke, and dyslipidemia.

Results
Clinical Characteristics
A total of 26 subjects were included in this study (n=12 AIS, n=14 control). The
demographic information for both AIS and control is included in Table 1. There were
several significant differences between AIS and control subjects. Control subjects were
significantly younger than AIS patients (p=0.002) and AIS patients had a significantly
larger proportion of patients with hypertension (p=0.003) and patients who had suffered
a previous ischemic stroke (p=0.019) (Table 1). In the AIS group, there were 3 mild
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severity, 3 moderate severity, and 6 severe severity cases. Further, the mean NIHSS of
the AIS group was 9.5 ± 5.8 (mean ± SD).

Relationship between Whole Blood ARG1 Expression and Neutrophil and Monocyte
ARG1 Protein Levels
There is no relationship between whole blood ARG1 and neutrophil ARG1 in the total
subject cohort (r=0.254, p=0.295) (Figure 1C). However, when the total group is split into
AIS and control subjects, there are relationships between whole blood ARG1 and
neutrophil ARG1 in each group separately. Specifically, there is a weak relationship
between whole blood ARG1 and neutrophil ARG1 in AIS patients (r=0.642, p=0.119)
(Figure 1A), and there is a weak relationship between whole blood ARG1 and neutrophil
ARG1 in control subjects (r=0.431, p=0.162) (Figure 1B). There was no relationship
between whole blood ARG1 and monocyte ARG1 within any of the group comparisons
(not shown). There was also no relationship between total leukocyte ARG1 protein
(neutrophil + monocyte ARG1 protein) and whole blood ARG1 expression (Figure 2).

Neutrophil and Monocyte ARG1 in AIS and Control Subjects
No intracellular ARG1 was detected in the lymphocyte subpopulation. Intracellular ARG1
was detected in both the neutrophil and monocyte fractions in both AIS and control
patients; however, neither neutrophil nor monocyte ARG1 levels significantly differed
between AIS and control (Figure 3). Further, in both AIS and control, ARG1 was detected
at a higher level in the neutrophil fraction compared to the monocyte fraction.
Neutrophil and Monocyte ARG1 in Mild and Severe AIS Patients
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Within the AIS group, neutrophil ARG1 was significantly higher in the severe group
compared to the mild AIS group (p=0.008) (Mean neutrophil ARG1 severe=665 ± 117;
mean neutrophil ARG1 mild/moderate=453 ± 108) (Figure 4). Further, after linear
regression analysis controlling for confounding variables, stroke severity remains a
significant predictor of neutrophil ARG1 (p=0.053).

Discussion
This is the first study to quantify intracellular ARG1 protein by Flow Cytometry in AIS
patients. Previous reports have established that ARG1 mRNA expression is highest in
neutrophils and second highest in monocytes compared to other leukocyte subsets in
healthy control subjects; however, these observations were not performed in AIS patients.
The first aim of this study was to determine if ARG1 protein was present in neutrophils
and monocytes, and if present, to establish whether ARG1 was higher in neutrophils
compared to monocytes. We found that in both AIS and control subjects, ARG1 protein
is expressed by both neutrophils and monocytes, and the neutrophil ARG1 protein
expression is significantly higher than in monocytes. These findings confirm and also
expand upon the previous observations that ARG1 mRNA expression was highest in the
neutrophils, and this relationship remains unchanged in response to AIS. Based on the
previous reports of elevated ARG1 expression in the whole blood of AIS patients
compared to control, we hypothesized that this elevated whole blood ARG1 expression
preceded upregulation of neutrophil ARG1 expression, and subsequently neutrophil
ARG1 protein expression in AIS compared to controls.
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Contrary to our hypothesis, we observed no significant differences in neutrophil
ARG1 protein expression between AIS and control subjects. While this was unexpected,
based on previous gene expression data, there are several plausible explanations for this
discrepant finding. First, the sample size in this study is extremely small, such that group
comparisons should be made cautiously, as outliers can strongly influence datasets with
a small number of subjects. To this end, it may be possible that the extreme values for
neutrophil ARG1 in each group masked the true median values for neutrophil ARG1.
Future studies with a larger sample size are warranted to further explore this hypothesis.
Second, the control group utilized in this study consisted largely of subjects with metabolic
syndrome (MetS). While MetS embodies AIS risk factors, making them a suitable control
group, the AIS risk factors for stroke, such as hypertension and obesity, may contribute
to altered neutrophil ARG1 expression. There have been no studies evaluating the effect
of AIS risk factors on ARG1 or neutrophil ARG1 protein to support this hypothesis, and
further studies would be required to determine the effect of AIS risk factors on ARG1
expression as a whole.
Also contrary to our hypothesis, there was no relationship between whole blood
ARG1 expression and neutrophil ARG1 protein expression. Again, while in disagreement
with our hypothesis, there are several possible explanations for this finding. First, because
changes ARG1 mRNA expression precede changes in both systemic and neutrophil
ARG1 protein expression, it may be possible that it is too early for a relationship between
ARG1 mRNA expression and neutrophil ARG1 protein to be observed. For example, it
may be possible that ARG1 mRNA expression would be correlated with neutrophil ARG1
quantified at a future time point; however in this study both ARG1 mRNA and neutrophil
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ARG1 were quantified at the same time point. It is also possible that whole blood ARG1
mRNA expression is not correlated with neutrophil ARG1 because whole blood ARG1
mRNA expression contributes to systemic ARG1 protein upregulation in cells other than
neutrophils. We attempted to address this by adding neutrophil and monocyte ARG1
together as a measure of “total” leukocyte ARG1. This is a loose definition of total
leukocyte ARG1, as there may be low levels of ARG1 protein expression from other
leukocyte subpopulations. Regardless, there was no relationship between our total
leukocyte ARG1 protein and whole blood ARG1 mRNA expression. This suggests that
ARG1 mRNA expression may contribute to translation/upregulation of ARG1 protein in
cell types other than leukocytes, such as red blood cells. Future studies should expand
the number of leukocyte subpopulations analyzed for ARG1 protein and also address
upregulation of ARG1 in red blood cells.
Despite the previous findings, concordant with our hypothesis, we did observe a
statistically significant difference in neutrophil ARG1 between mild and severe AIS.
Specifically, ARG1 protein is higher in neutrophils in severe AIS compared to mild AIS.
This finding suggests there may be an upregulation in neutrophil ARG1 in response to
stroke that is dependent on AIS severity. We have previously shown that whole blood
ARG1 mRNA expression is positively correlated with stroke severity, and taken together
with this novel finding of increased ARG1 protein in neutrophils supports the concept that
increased ARG1 protein contributes to increased AIS severity. This finding should be
interpreted cautiously, given the previous finding that there was no relationship between
whole blood ARG1 expression and neutrophil ARG1 protein expression.
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Overall, the results of this study suggest that ARG1 protein expression is highest
in neutrophils compared to other leukocyte populations. Neutrophil ARG1 may also
increase in response to brain damage in severe AIS. Because increased ARG1 protein
released from neutrophils has been shown to exacerbate AIS damage in a rodent model
of stroke, these findings suggest that inhibition of systemic ARG1 protein may improve
AIS outcome, and neutrophils may be a therapeutic target for ARG1 inhibition.
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Figure 1: Relationship Between Whole Blood ARG1 mRNA Expression and
Neutrophil ARG1 Protein in AIS and Control.
(A) There is a weak relationship between whole blood ARG1 and neutrophil ARG1 in
AIS patients (r=0.642, p=0.119).
(B) There is a weak relationship between whole blood ARG1 and neutrophil ARG1 in
control subjects (r=0.431, p=0.162).
(C) There is no relationship between whole blood ARG1 and neutrophil ARG1 in the
total subject cohort (control and AIS combined) (r=0.254, p=0.295).
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Figure 2: Relationship between Total Leukocyte ARG1 Protein and Whole Blood
ARG1 mRNA Expression. There is a weak relationship between total leukocyte ARG1
protein (neutrophil + monocyte ARG1 protein) and whole blood ARG1 mRNA expression
(r=0.319, p=0.184).
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Figure 3: Intracellular ARG1 Staining in Leukocyte Subpopulations in AIS and
Control Subjects. Intracellular ARG1 was detected in both the neutrophil and monocyte
fractions in both AIS and control patients; however, neither neutrophil nor monocyte
ARG1 levels significantly differed between AIS and control (mean neutrophil ARG1
AIS=558 ± 154; mean neutrophil ARG1 control=620 ± 145; mean monocyte ARG1
AIS=281 ± 72; mean monocyte ARG1 control=248 ± 18).
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Figure 4: Intracellular ARG1 Staining in Leukocyte Subpopulations in AIS Patients
by Stroke Severity. Within the AIS group, neutrophil ARG1 was significantly higher in
the severe group compared to the mild AIS group (p=0.008) (Mean neutrophil ARG1
severe=665 ± 117; mean neutrophil ARG1 mild/moderate=453 ± 108).
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CHAPTER 7: GENERAL DISCUSSION

The specific aims of this dissertation were to: (1) Determine the Relationship Between
ARG1, NLR, and AIS severity, (2) Characterize the Role of ARG1 in Mediating CV
Function following AIS, and (3) Determine the Cellular Origin of ARG1 and Functional
Role of ARG1 in AIS. Chapters 2 and 3 represent data to support specific aim 1, chapters
4 and 5 represent data to support specific aim 2, and chapter 6 supports specific aim 3.

Chapter Summaries
Chapter 2
The results of chapter 2 were published in the peer-reviewed journal, Translational Stroke
Research. The purpose of this study was: (1) To examine the relationship between ARG1,
NLR, and AIS severity. We hypothesized that increased ARG1 expression and serum
protein activity is associated with an increased NLR, giving rise to increased AIS severity
and poor outcome; (2) To validate the role of ARG1 as a novel biomarker of immune
suppression in AIS; and (3) To Utilize Principal Component Analysis (PCA) to statistically
model multiple gene expression changes following AIS.
In support of our hypothesis, we found that both increased ARG1 mRNA and
serum activity are positively correlated with AIS severity and NLR, and increased NLR
was associated with increased AIS severity. PCA also supported a model of increased
ARG1 and MMP9 and decreased CCR7 as a pattern of expression associated with AIS
severity and NLR.

133

This study was characterization of the relationship between ARG1, NLR, and AIS
severity; however, while the associations were strongly significant, there is no evidence
for a functional role of the biomarkers described in this study. This is a limitation of
biomarker studies as a whole, which is especially true for gene expression analysis.
Because changes in gene expression are not always strongly correlated in changes in
protein expression or activity, functional interpretation of gene biomarker analysis should
be approached cautiously. With that being said, in addition to gene biomarkers, we also
measured serum arg1 activity to provide more insight into the functional role of ARG1.
Serum ARG1 activity was strongly correlated with ARG1 mRNA expression that suggests
for ARG1, changes in gene expression are correlated with changes in protein activity.
Further, ARG1, MMP9, and s100a12 were found to be the most significantly elevated
genes in our panel in AIS compared to control. All 3 of these genes are highly expressed
by neutrophils, so the possibility exists that increases in these biomarkers reflect an
increase in neutrophil count, rather than a functional mechanism contributing to AIS
severity. It is my opinion that changes in ARG1 and MMP9 represent functional changes
in AIS, whereas s100a12 may be simply a marker of neutrophil count following AIS.
S100a12 is a calcium-binding protein that is constitutively expressed by neutrophils and
has not been shown to have any relationship to AIS in any other context. MMP9 is also
constitutively expressed by neutrophils; however, MMP9 is highly expressed by several
leukocytes, especially innate immune cells. MMP9 release aids in cell migration into the
brain following AIS, but also contributes to BBB disruption and AIS severity. Addition of
serum MMP9 activity would be useful to determine if MMP9 has a potential functional role
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in AIS; however, the functional role of MMP9 in AIS has been extensively described, so
it is unlikely that MMP9 is only a marker of neutrophil count.
Another limitation of this study is that the AIS cases were not split by AIS subtype,
and there have been several studies that suggest that different patterns of biomarker
expression are associated with different AIS subtypes. It may be possible that in this small
sample size, the gene expression patterns we observed were associated with a specific
AIS subtype, rather than AIS as a whole, if this dataset contains an unequal distribution
of AIS subtypes. For example, large artery AIS is associated with carotid atherosclerosis,
and because we know that ARG1 expression contributes to atherosclerosis formation, it
may be possible that differences in ARG1 expression are due to risk factors prior to
stroke, rather than an acute response to AIS itself. Unfortunately, Ruby Memorial Hospital
does not classify AIS subtype using TOAST or any other sub-typing system; therefore,
we were unable to consider this in our analysis. Further, given the limited sample size, it
would have been difficult to perform meaningful statistical analysis on small groups split
by AIS subtype.
Lastly, we were unable to obtain NLR and serum ARG1 activity in our control
group. This was a logistical issue related to how our control patients were collected. A
bulk of the control subjects included in this analysis were obtained via recruitment for the
study described in Chapter 5, and because we were recruiting a remote, rural setting,
serum isolation was not feasible for these samples. Further, while NLR may have been
obtained, the NLR was not a primary outcome measurement during the planning of this
study, but will likely be added to the protocol for future studies. This would be useful for
several reasons, but it would be crucial to measure neutrophil count in controls, and my
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hypothesis is that neutrophil counts would be similar between groups, however that ARG1
would still remain elevated in the AIS group, indicating a functional role of ARG1,
independent of neutrophil count alone.
Chapter 3
The aim of this study was to expand upon the finding that baseline NLR is associated with
AIS severity and outcome and determine if measuring the NLR after thrombolysis or at
several time points following AIS provide greater insight into stroke severity and outcome
than baseline NLR. We hypothesized that an increase in NLR following thrombolysis is
associated with increased severity and poor outcome, regardless of the baseline NLR
value prior to treatment.
While the findings of this study lacked statistical significance, there is evocative
evidence to suggest that not only can the baseline NLR be used to stratify AIS patients
according to severity, but also that measuring the change in NLR following thrombolysis
may also be indicative of acute severity, and may be a stronger indicator of outcome
compared to baseline NLR.
Chapter 4
The aims of this study were to: (1) Characterize the changes in ARG1 expression that
occur in response to AIS, (2) Characterize the changes in cfPWV that occur in response
to AIS, and (3) To determine if ARG1 expression may be a functional mediator of vascular
function, specifically cIMT and cfPWV, following AIS.
We hypothesized that increases in both ARG1 expression and cfPWV would be
associated with increased baseline stroke severity and poor outcomes. We also
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hypothesized that ARG1 expression is correlated with cfPWV at both baseline and during
AIS recovery.
Our results supported our hypotheses, specifically, there is a strong unadjusted
relationship between baseline ARG1 expression and baseline NIHSS. In mild AIS, cfPWV
remains stable from baseline to 30 days post-stroke. In contrast, cfPWV increased from
baseline to 30 days post-stroke in severe AIS. Lastly, there appears to be a relationship
between ∆ARG1 and ∆cfPWV from baseline to 30 days post-stroke. However due to the
small sample size further study in this area is warranted to back up our initial findings.
Chapter 5
The goal of this study was to characterize the changes in ARG1 expression, as well as
cIMT and cfPWV, following a 10-week lifestyle modification. We hypothesized that
decreases in CV risk factors, such as cIMT, cfPWV, blood pressure, and body weight, will
correlate with decreases in ARG1 expression.
First, similar to previous reports, we confirmed the strong relationship between
cIMT and cfPWV. In contrast to our hypothesis, there were no associations between
decreased body weight, cholesterol, triglycerides, increased functional exercise capacity,
and cfPWV. However, in support of our primary hypothesis, we did observe a strong
correlation between the 10-week ∆cfPWV and ∆ARG1 expression, supporting our
hypothesis that ARG1 may be a functional mediator of cfPWV.
Chapter 6
The aims of this study were to expand upon previous studies to (1) Determine
whether ARG1 protein, in addition to mRNA expression, is highest within neutrophils
compared to other leukocyte fractions, (2) Determine if neutrophil ARG1 protein levels
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differ between AIS and control and (3) Characterize the change in neutrophil ARG1
protein that may occur with increasing AIS severity. We hypothesized that ARG1 protein
would be highest in neutrophils compared to other leukocyte populations in both AIS and
control; however, ARG1 protein levels would be higher in the neutrophils of AIS patients
compared to controls. Further, we hypothesized that within the AIS group, neutrophil
ARG1 protein levels will be higher in severe AIS compared to mild.
We found that in both AIS and control subjects, ARG1 protein is expressed by both
neutrophils and monocytes, and the neutrophil ARG1 protein expression is significantly
higher than in monocytes. Contrary to our hypothesis, we observed no significant
differences in neutrophil ARG1 protein expression between AIS and control subjects. Also
contrary to our hypothesis, there was no relationship between whole blood ARG1
expression and neutrophil ARG1 protein expression.

Limitations
Small Sample Size
An overall limitation of this dissertation was small sample sizes, as compared to other
clinical studies. The following sections, including power analyses, barriers to subject
recruitment, and future study design will specifically address sample size concerns,
provide an explanation for sample sizes, and also provide a strategy to improve upon
these limitations in future studies.

Power Analyses
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Post-hoc power analyses were conducted to determine achieved power, given alpha
level, sample size, and effect size using G*Power3.
Chapter 2
We performed two independent power analyses for the two primary aims of the study: (1)
To evaluate the relationship of ARG1 and stroke severity, as measured by NIHSS, and
(2) To compare ARG1 expression between stroke and control. Using a linear regression
model, controlling for seven predictors (age, sex, smoking, hypertension, hyperlipidemia,
diabetes and prior stroke), we determined that our sample size of n=26 and effect size
1.5 was sufficient to detect differences in ARG1 expression along the NIH stroke severity
score scale with 88% power at an alpha level of 0.05. Using a linear regression model,
controlling for eight predictors (case (control v. stroke), age, sex, smoking, hypertension,
hyperlipidemia, diabetes, and prior stroke), we determined that our sample size n=45 and
effect size 0.5 was sufficient to detect differences in ARG1 expression between stroke
and controls with 99% power at an alpha level of 0.05. Of all the chapters in this
dissertation, this was the only study that achieved desired statistical power.
Chapter 3
We determined that our sample size of n=18 and effect size of f=0.25 was able to detect
differences in NLR between mild, moderate, and severe AIS groups with only 12% power
at an alpha level of 0.05, using a repeated measures ANOVA. A sample size of 159
subjects would be necessary to a small effect (f=0.25) between groups with 80% power
at an alpha level of 0.05.
Chapter 4
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We determined that our sample size of n=12 and effect size of f=0.3 was able to detect
differences in ARG1 expression in relationship to cIMT and cfPWV with only 817% power
at an alpha level of 0.05. A sample size of 82 subjects would be necessary to a small
effect (f=0.3) with 80% power at an alpha level of 0.05.
Chapter 5
We determined that our sample size of n=12 and effect size of f=0.3 was able to detect
differences in ARG1 expression in relationship to cIMT and cfPWV with only 817% power
at an alpha level of 0.05. A sample size of 82 subjects would be necessary to a small
effect (f=0.3) with 80% power at an alpha level of 0.05.
Chapter 6
We determined that our sample size of n=26 and effect size f=0.25 was able to detect
differences in neutrophil ARG1 levels between AIS and control with only 23% power at
an alpha level of 0.05, using a repeated measures ANOVA. We also determined that our
sample size of n=12 AIS patients and effect size f=0.25 was able to detect differences in
neutrophil ARG1 levels between mild and severe AIS with only 12% power at an alpha
level of 0.05, using a repeated measures ANOVA. A sample size of 128 subjects would
be necessary to a small effect (f=0.25) between both stroke and control and mild and
severe AIS, with 80% power at an alpha level of 0.05.
Barriers to Subject Recruitment
Because Ruby Memorial Hospital receives ~ 1200 stroke pages annually and it is
estimated that roughly one third or 400 of those pages are stroke cases. Of that estimated
400 cases, approximately 320 are ischemic strokes. With that being said, our laboratory
is often asked why our annual subject enrollment is substantially less than the number of
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ischemic stroke patients presenting to Ruby Memorial Hospital. There are several factors
that can be considered as barriers to subject recruitment in our studies.
The first and largest barrier to subject recruitment is the requirement for an
imaging-confirmed stroke diagnosis, in order to be eligible for enrollment in our studies.
This means that no stroke patient is eligible for enrollment into our study without a CT or
MRI image, confirming the presence of an ischemic infarct, and this image must also be
obtained prior to intervention, such as tPA administration or mechanical clot removal.
While stroke imaging is certainly a part of clinical care at Ruby Memorial Hospital, not all
patients that will be discharged with a stroke diagnosis, and therefore contribute to the
annual number of stroke cases reported at Ruby, are confirmed by imaging. There are a
substantial number of cases that are diagnosed as stroke, on the basis of clinical
presentation and physician impression, even in the absence of positive imaging.
The second largest barrier to recruitment is the time at which stroke patients
present to the emergency department. Our laboratory staff and work coordinators typically
work a 9am-5pm schedule, thus stroke patients who arrive between the hours of 5pm-9
am the next morning are difficult to enroll in the study. Because we are approved to enroll
stroke patients within 24 hours of symptom onset, some of these patients who arrive
“after-hours” may still be eligible for our studies if they have not undergone any
intervention, such as tPA administration or mechanical clot removal; however, a large
number of patients will have already treated in the time that our staff is unavailable for
recruitment. To increase subject enrollment during our typical working hours, for a short
period of time during the duration of this dissertation, we had a nurse coordinator who
was in charge of recruitment from 7pm-8am, and we expected to see dramatic increases
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in subject recruitment. To our surprise, this extra staff did not lead to a large increase in
subject recruitment, thus while it may be a strategy to employ in the future, the largest
barrier to subject recruitment was not a matter of laboratory staff availability and effort,
but due to the first barrier to recruitment mentioned above.

Future Directions
Study Design
In addition to simply increasing sample size in our studies, future studies should also use
different clinical trial designs to make even small sample sizes more meaningful. An
adaptive clinical trial is a clinical trial that is guided by prospectively planned interim data
analyses during the course of the trial that may prompt changes in the trial design to make
the studies more efficient. These changes in trial design can include, but are not limited
to, changes in eligibility criteria, treatment regimens, sample size, and statistical
interpretation. For example, an adaptive clinical trial monitoring the efficacy of a new
therapeutic agent for stroke may be approved at the start of the trial for multiple doses,
but if an interim analysis conducted into the study suggests that only certain doses are
effective, the trial will then be modified, such that patients enrolled after the interim
analysis will receive the doses deemed to be effective in the interim analysis. These
frequent interim analyses and adaptations make clinical trials more efficient by both
reducing the number of patients needed to show efficacy in a clinical trial and by reducing
the duration of the trial. This improved efficacy will result in a shorter amount of time that
it takes for novel, beneficial therapeutic agents to reach the clinical population.
Experimental Studies
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CCR7
CCR7 is a membrane-bound receptor located on T lymphocytes that is required for
homing to secondary lymphoid organs prior to activation. We have shown that CCR7
expression is decreased in AIS compared to control, and CCR7 expression is negatively
correlated with AIS severity. We have also established that CCR7 downregulation may
be linked to an increase in ARG1 expression. Interestingly, while ARG1 has been shown
to inhibit T cell proliferation by downregulation of the TCR complex, decreased CCR7 has
not been implicated in immunosuppression in animal models of AIS. Further, there have
been no studies evaluating CCR7 overexpression on AIS outcomes. It is unclear why
CCR7 has been identified, as a biomarker in human AIS studies, yet has not surfaced in
animal models of AIS, considering CCR7 is expressed and has the same function in both
humans and animals. With that being said, many clinical trials for AIS therapeutics fail
because animal models fail to translate to humans, whereas CCR7 may be a therapeutic
target in AIS that is identifiable in humans, but lacks relevance in animals. My hypothesis
is that because CD3 has not been shown to be significantly decreased in human AIS
studies, ARG1 may induce immunosuppression may induce immunosuppression through
downregulation of CCR7 rather than CD3 in humans.
ARG1 Inhibition
Given that ARG1 inhibition is currently in clinical trials for use in myocardial ischemiareperfusion injury, it is surprising that there have been no experimental models evaluating
ARG1 inhibition in the context of AIS. Given the recent studies, evaluating the role of
ARG1 in post-stroke immunosuppression, I believe that these studies may have already
been performed and will be published in the near future. Given its success in myocardial
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ischemia-reperfusion injury and the data presented in this dissertation, I believe that
ARG1 inhibition may be a therapeutic target, both acutely and chronically, following AIS.
In terms of chronic ARG inhibition, there have been no studies to evaluate what
effect chronic ARG inhibition would have systemically. Theoretically speaking, ARG1
inhibition would result in increased bioavailability of NO and increased vasodilation. There
are no instances where increased vasodilation could be harmful, so in my opinion, chronic
ARG1 inhibition would have no ill effects on vascular function. There is a possibility that
chronic ARG1 inhibition would lead to the development of autoimmune conditions, given
the potential role of ARG1 as immunosuppressive. If ARG1 inhibition would be considered
as a chronic treatment for CV risk factors or long-term following AIS, clinical trials would
be needed to evaluate the safety and off target effects.
Retrospective Analysis on AIS in Arginase Deficiency
Along the lines of chronic ARG inhibition, while rare, there are reported cases of ARG
deficiency in humans. This is a non-lethal, genetic disorder that generally requires no
treatment, other than diet modification to limit protein, I.e. L-arginine, intake. While there
is no screening data currently for this disorder, a retrospective analysis with data from
these patients would be interesting to evaluate AIS incidence, severity, and recovery. It
also supports the hypothesis that chronic ARG1 inhibition should have no severe side
effects on the system.

ARG1 Expression by Red Blood Cells
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While gene expression biomarkers in peripheral whole blood are considered to be
reflective of changes in leukocytes, red blood cells have also been to express several
mRNA molecules, despite the lack of a nucleus. In terms of AIS, the upregulation following
AIS may be due to upregulation by red blood cells. This may explain why neutrophilinhibition therapies have been unsuccessful in AIS clinical trials may be partially due to
the fact that ARG1 is still being generated by other sources, including RBCs. Isolation of
RBCs in AIS patients and measuring ARG1 expression in RBCs following AIS in addition
to WBC subtypes would be an easily performed experiment to address the role of RBCderived ARG1 in AIS.
ARG1 Gene Expression on WBC Subsets following Stroke
To our knowledge, there has been only one study evaluating ARG1 mRNA expression on
individual leukocytes. This study only addressed leukocyte-ARG1 expression in 3 control
subjects and determined that ARG1 is highest in neutrophils and monocytes; however, it
is currently unknown whether ARG1 is upregulated in these cell types in a severitydependent manner following AIS or if ARG1 expression increased in other leukocytes
following AIS.
Preventing ARG1 Release for ARG1 Protein Analysis by Flow Cytometry
This is logistic improvement from our studies performed in chapter 6, determining the
cellular source of ARG1 protein following AIS. This study addressed the hypothesis of a
severity-dependent increase in ARG1 by neutrophils following stroke. While we did see
an elevation in neutrophil ARG1 in severe compared to mild stroke, we did not see an
increase in total stroke compared to control, which makes us interpret the severitydependent increase in ARG1 cautiously. When comparing AIS to control, we actually
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observed a non-significant decrease in neutrophil ARG1 in AIS compared to control.
Because ARG1 is likely secreted from neutrophils in granules, it may be possible that we
observed this expression because more ARG1 is released from neutrophils in AIS
compared to control. To address this, isolated WBCs can be treated with a chemical that
prevents proteins from being exported from the cell, thus secreted proteins can be
quantified, because they accumulate in the cell. It is necessary to consider this in future
studies.
NLR at Multiple Time Points
While we examined the NLR at both baseline and 48 hours following AIS, measuring the
NLR at later time points, 7,30, and 90 days following AIS, may be more indicative of poststroke immunosuppression, as increased rate of infection in AIS patients is not observed
until roughly one week following AIS. We have approval to collect NLR at these time
points; however, because a WBC differential is not collected at these follow-up visits as
a standard of clinical care, incomplete data on our patients made this analysis less
meaningful.
T Lymphocyte Subset Specific NLR
In addition to the basic NLR described in this document, there are several variations of
the NLR that may have more utility in AIS. The NLR referred to in this document is (total
neutrophil count/ total lymphocyte count), thus will be influenced by both B and T
lymphocyte counts. B lymphocytes have been shown to play a role in AIS, albeit less
prominent than T lymphocytes, such that this version of the NLR may be complicated by
the interplay between B and T lymphocytes. The first variation of the NLR that could be
useful in stroke would be a T lymphocyte-specific NLR calculated by (total neutrophil
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count/ total T-lymphocyte count). Because decreased T lymphocyte counts and function
are indicative of NLR, this variation of the NLR may be more predictive of post-stroke
immunosuppression. Unfortunately, clinical WBC differentials do not distinguish B and T
lymphocytes, thus determination of this NLR would likely be performed manually by flow
cytometry. In my opinion, this variation of the NLR would have the most utility in predicting
AIS severity and post-stroke immunosuppression, and it would be measured by
(neutrophil count/T lymphocyte subset count). Because we know that different T subsets
play very different roles in AIS, these NLRs could yield very different information,
especially if measured at multiple time points. I hypothesize that increased (neutrophil
count/Treg count) would be most predictive of post-stroke immunosuppression and poor
outcome, due to the beneficial role of TReg cells compared to other T subsets following
AIS.
The Effect of ARG1 on T Lymphocyte Subsets
Similar to the direction suggested above, it is possible that ARG1 impacts T cell
proliferation in a subset-dependent manner. For example, it may be possible that Treg
cells are more susceptible to ARG1-mediated inhibition than CD8+ T cells or vice versa.
Thus, it would also be important to examine the relationship of ARG1 to a T-subset
specific NLR to provide better insight into the functional role of ARG1 in mediating the
NLR.
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